Mechanisms of Lung Surveillance by Pathogen-Specific Cytotoxic T Lymphocytes by Lee, Young-Tae
University of Connecticut
OpenCommons@UConn
Doctoral Dissertations University of Connecticut Graduate School
2-7-2013
Mechanisms of Lung Surveillance by Pathogen-
Specific Cytotoxic T Lymphocytes
Young-Tae Lee
leechard75@gmail.com
Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Lee, Young-Tae, "Mechanisms of Lung Surveillance by Pathogen-Specific Cytotoxic T Lymphocytes" (2013). Doctoral Dissertations. 4.
https://opencommons.uconn.edu/dissertations/4
 MECHANISMS OF LUNG SURVEILLANCE  
BY PATHOGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES 
Young-Tae Lee, Ph.D. 
University of Connecticut, 2013 
 
Cytotoxic T lymphocyte (CTL)-mediated immunity plays a critical role 
in clearance of influenza virus-infected cells through contact-dependent 
interactions. Recent studies have described stationary tissue-resident 
memory (Trm) T cells which maintain CD69 and CD103 expression in 
peripheral tissues after local infections. These Trm cells are believed to 
contribute to protection after local reinfection, because they stay near the site 
of inoculation. Parabiosis studies previously showed that some non-migratory 
virus-specific CD8 T cells expressed both CD69 and CD103 in the airways 
after influenza virus infection. Since the TGFβ and TcR signaling pathways 
induce CD103 and CD69 expression on CD8 T cells in other models, I 
hypothesized that environmental factors and residual viral products support 
sustained surveillance of the lungs by pathogen-specific CTLs. In chapter 3, I 
used mice that express a dominant negative form of the TGFβRII 
(dnTGFβRII) to investigate the role of TGFβ signals in regulation of virus-
specific CTL responses in the lungs after influenza virus infection. My data 
showed that TGFβ signals were necessary to reduce numbers of KLRG1+ 
virus-specific Teff cells which were capable of making effector cytokines 
during early infection. In addition, TGFβ signals were required for CD103 
expression on virus-specific CTLs that were retained in the lungs during the 
recovery stage of the infection. In chapter 4, I examined how antigen-
persistence changes the virus-specific CTL response in the lungs using 
recombinant influenza viruses that differ in their ability to support prolonged 
antigen presentation. Comparisons of the CTL that responded to these 
viruses showed that prolonged antigen presentation reinforced expression of 
CD69 on virus-specific CTLs in the lung tissues, but not in the airways. I also 
used transfer studies to determine how CD69 influenced CD8 T cell migration 
in the lungs. Confocal microscopy showed that some CD69KO CTLs were 
collected around the blood vessels during the late stage of the infection. My 
data provide new insights into the generation and maintenance of virus-
specific Trm cells in the lungs. CD69 and CD103 are both required for 
maintenance of long-lived Trm cells in the local tissues where they can 
provide immediate protective immunity against serologically distinct strains of 
influenza viruses. 
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1. CHARACTERISTICS OF INFLUENZA VIRUSES 
 
A. Influneza virus and human health 
Influenza viruses are highly contagious pathogens which cause severe respiratory 
disease with symptoms such as fever, nausea, headache and pulmonary congestion. 
Seasonal variants cause high levels of morbidity and mortality annually, which mostly 
include elderly and sick people. These virues cause 36,000 deaths and more than 
200,000 hospitalizations in the United States each year [1;2] with around 300,000 - 
500,000 deaths and 3 - 5 million hospitalizations around the world [3]. In addition to these 
annual epidemics, new strains of influenza virus can cross between species and cause 
occasional pandemics which can spread through human populations around the world. 
The viruses continually change due to high mutation rates and a segmented viral 
genome which can reassort to produce new strains [4].  
 
Influenza viruses are from the A genus of the Orthomyxoviridae family which are 
common pathogens of the respiratory track [4;5]. Based on antibody reactivity with their 
surface glycoproteins, which are hemagglutinin (HA) and neuraminidase (NA), influenza 
A viruses can be divided into several serotypes. Many serotypes have been identified in 
birds (H1-H16 and N1-N9), but only a few subtypes replicate efficiently in humans [6]. 
Currently, most seasonal infections are caused by influenza A H1N1 and H3N2 subtypes 
and influenza B viruses. Evolutionary pressure causes constant antigenic drift leading to 
escape mutations which avoid the host’s previous antibody response [7]. In addition 
when two different viruses infect the same cell the segmental genome can create a third 
reassortant strain. This process can be helped by an intermediate host such as the pig  
[8]. To protect humans from influenza virus infections antibody based vaccines must be 
designed for different subtypes.  
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  Major influenza pandemics have occurred three times in the twentieth century 
and once in the twenty first century. Between 1918-1919 the first documented H1N1 
influenza virus caused an outbreak known as the “Spanish influenza pandemic”, which 
resulted in more than 40 million deaths around the world and was the most devastating 
outbreak of influenza so far [9]. The HA gene in the 1918 virus did not contain some 
highly virulent sequence motifs which have been identified in the H5N1 avian influenza 
virus that is currently prevalent in birds [10;11]. It has been demonstrated that the variant 
of HA that was encoded in the 1918 virus played a pivotal role in the pathogenicity of the 
infection, while the NA protein did not play a major role [12]. Variants of the H1N1 strain 
still circulate in human populations, but in 1957 a second pandemic called the Asian 
influenza H2N2 strain developed, when the HA (H2), N2 and PB1 genes were replaced 
with genes from a new avian strain [13, 14]. Another pandemic developed in Hong Kong in 
1968, which was caused by a reassortant A/H3N2 subtype. This virus contained new 
avian HA (H3) and PB1 genes in the background of the human 1957 H2N2 virus [8]. The 
most recent pandemic developed in 2009 and was caused by a new A/H1N1 variant 
which originated from swine leading to the first pandemic in the 21st century [4]. Other 
avian influenza viruses can also infect humans but do not spread efficiently between 
people including H7N7, H7N3, H9N2 and H10N7 [8, 15], as well as the new H5N1 strain 
that began to infect some humans in 1997. This is a highly pathogenic avian influenza 
virus (HPAI) can be transmitted to humans from domestic poultry [16, 17].  
 
Some  influenza virus infections are complicated by secondary bacterial infections 
which can lead to lethal pneumonia [18]. Many people who died during the 1918 
pandemic had bacterial infections in the lungs. In addition, more than two-third of the 
deaths during the 1957 pandemic were associated with bacterial pneumonia [19]. Current 
data suggest that influenza viruses cause immune suppression, which leads to 
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secondary infections with common gram-negative bacteria including Staphylococcus 
aureus, Haemophilus influenza and Streptococcus pneumonia [18;20]. 
 
B. Influenza virus entry and replication in the lungs 
Influenza A viruses contain eight negative-stranded RNA segments which encode 
11 different proteins, which are hemagglutinin (HA), neuraminidase (NA), nucleoprotein 
(NP), polymerase acidic protein (PA), matrix protein 1 (M1), matrix protein 2 (M2), non-
structural protein 1 (NS1), nuclear export  protein (NEP; NS2), polymerase basic protein 
1 (PB1), polymerase basic protein 2 (PB2) and PB1-F2 which is encoded by a shifted 
reading frame in the PB1 gene. The virus envelope contains two major glycoproteins 
which are HA and NA [8], which are the major targets of the humoral immune response 
[7]. Some conserved internal proteins such as the polymerase acidic protein (PA), 
polymerase basic protein 2 (PB2) and nucleoprotein (NP) contain epitopes that are 
targeted by the cellular immune response [8].  
 
The respiratory track has a very large surface area which provides an entry point for 
a wide range of pathogens to enter the body [21]. The lungs are protected by many 
mechanisms including ciliated epithelial cells which help expel inhaled antigens via the 
mucociliary escalator [22]. When the virus enters the host cells, HA binds to sialic acid 
residues with terminal oligosaccharides which are primarily found on the lung epithelial 
cells. Avian influenza viruses preferentially interact with sialic-acids with  galactose with 
α-2,3 linkages, while human influenza viruses preferentially bind to sialic acid residues 
with α-2.6 linkages [23]. The lung epithelial cells are an important target for influenza 
virus infection because they express a trypsin-like protease which is required for 
cleavage of hemagglutinin (HA0) into HA1 and HA2. This cleavage releases the carboxyl 
terminus of HA1 and produces the amino terminus HA2 protein which is essential for 
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membrane fusion and to release the viral genome into the cytoplasm of the host cells 
during the production of infectious influenza virus [24-26].  The three external proteins that 
are located in the lipid bilayer of the viral envelope are HA, NA and M2 which play a 
pivotal role in the life cycle of influenza A virus.  The M2 protein forms a channel which 
induces endosome acidification, leading to uncoating of the virion [8;27]. In addition, the 
acidic pH in the endosome induces a conformational change of HA, to allow the 
exposure of internal amino acid groups, which is required for the insertion of fusion 
peptides into the host membrane. Eventually, the membrane breaks and a fusion pore 
allows individual viral RNPs (vRNAs) to be released into the host cytoplasm. Viral 
genomes are transported into the nucleus via nuclear localization signals (NLS) which 
interact with the NP protein [7] . When the NP, NS1 and NS2 proteins are newly 
synthesized they are transported into the nucleus and viral replication begins from a 
template RNA that is used to make full-length complementary RNA (cRNA) via a primer-
independent mechanism. The M1, NS2 and NP proteins help transport the vRNPs into 
the cytoplasm. Once inside the host cells these proteins move to the plasma membrane 
where the HA and NA proteins accumulate and form a budding site. Finally, the NA 
glycoprotein helps release the progeny viruses from the infected host cells via cleavage 
of sialic acids which are bound to new HA proteins [7].  
 
2. IMMUNE RESPONSE AGAINST INFLUENZA INFECTION 
 
A.  Innate immunity 
i. Sensing of influenza virus by innate recognition receptors 
Influenza virus infection elicits host immune responses which are crucial to stop viral 
replication. The innate immune system provides the first line of defense against 
influenza virus infection. When influenza viruses enter the host cells, they are 
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recognized by pattern recognition receptors (PRRs) such as toll-like receptor 7 (TLR7), 
retinoic acid inducible gene I (RIG-I) and the NOD-like receptor family pyrin domain 
containing 3 (NLRP3) protein, which can recognize pathogen-associated molecular 
patterns (PAMPs) of influenza virus [28]. Endosomal TLR7 can detect single-stranded 
RNA and cytoplasmic RIG-I recognizes 5’-triphosphate viral RNA[29]. Furthermore, 
activated RIG-I  binds to the mitochondrial antiviral signaling protein (MAVS) which 
activates NF-kB to induce proinflammatory cytokines [29]. Signals from these receptors 
result in the production of proinflammatory and antiviral cytokines such as IL-6, IL-12, 
and type I interferon α/β [30-32]. Proinflammatory IL-6 and IL-12 play a role in the cytotoxic 
response by enhancing virus-specific CTL activity to produce interferon gamma (IFNγ) 
and tumor necrosis factor alpha (TNFα) [33]. In addition, recent studies have 
demonstrated that NLRP3 inflammasome activation plays a crucial role in the detection 
of influenza viruses when caspase-1 activates the immature forms of pro-IL-1β and pro-
IL-18 [34;35]. Production of  IL-1β and IL-18 is important to recruit monocytes and 
neutrophils into the lung through a process that requires two signals such as TLR (signal 
1) and various stress signals including potassium efflux and cell membrane perturbation 
(signal 2) [29]. A recent study has shown that the M2 ion channel plays an important role 
in inflammasome activation by the induction of ion imbalance in cytoplasm (signal 2) [36]. 
These data show that influenza virus can provide both signal 1 (TLR7) and signal 2 
which result in inflammasome activation [29]. 
 
ii. Influenza viruses interfere with the innate immune system 
Some influenza virus encoded proteins can interfere with the host immune response. 
The non-structural protein (NS1) disturbs the nuclear export of mRNA by forming a 
complex with the nuclear-export machinery [37]. In addition, NS1 targets the ubiquitin 
ligase TRIM25 which is essential for RIG-I mediated antiviral activity, resulting in evasion 
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from recognition of retinoic acid-inducible gene I (RIG-I) [38] and reduces production of 
the interferon α/β and proinflammatory cytokines [39;40]. Recent studies have 
demonstrated that NS1 is capable of preventing infected DC from maturating, 
suggesting that its activity influences both innate and adaptive immune responses [41;42]. 
The influenza virus PB1-F2 is an 87-amino acid protein which is encoded by an alternate 
reading frame of the PB1 gene. It plays a role in triggering apoptosis of infected cells via 
mitochondrial permeablilization, resulting in the release of cytochrome C that  interacts 
with capase-9 [43]. In addition, PB1-F2 inhibits production of type I interferon by binding 
the MAVS adaptor protein [44]. 
 
iii. The role of innate immune cells in response to influenza virus infection 
During influenza virus infection many innate immune cells are involved in the 
clearance of the virus or virus infected cells. Natural killer (NK) cells contribute to the 
elimination of some infected cells and produce large amounts of proinflammatory 
cytokines such as IFNγ and TNFα. In fact, Fc receptor-bearing NK cells can recognize 
antibody-bound infected cells and lyse them by releasing perforins and granzymes [45]. 
In addition, NKp44 and NKp46 which are cytotoxicity receptors can bind to 
hemagglutinins and lyse influenza-infected cells by enhancing granzyme B and perforin 
secretion [46-48]. 
 
There are two major types of phagocyte cells in the lungs, which are alveolar 
macrophage and dendritic cells (DCs). Resting alveolar macrophages produce low 
levels of inflammatory cytokines. Upon influenza virus infection, the numbers of alveolar 
macrophages increase and they phagocytose influenza virus-infected cells. Activated 
alveolar macrophages also produce TNFα and nitric oxide synthase 2 (NOS2) which is 
plays a role in inflammation. In the latter case macrophages can contribute to pathology 
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in the lungs [49;50].  Alveolar macrophages are thought to have regulatory function by 
production of IL-10 and transforming growth factor-β (TGFβ) which are anti-inflammatory 
cytokines [51]. 
 
DCs are professional antigen presenting cells (APCs) which play a pivotal role in 
connecting the innate and adaptive immune responses. DCs are innate immune cells 
that have the capacity to recognize PAMPs using PRRs including TLR and NOD-like 
receptors (RLRs) [52]. In the murine model there is evidence that CD11b+ DCs mainly 
express TLR2 and TLR7, while CD103+ DC mainly express TLR3 [53]. However, both 
CD11b+ and CD103+ DCs express low levels of TLR4. Upon influenza virus infection, 
the conventional DCs are thought to utilize RIG-I to recognize influenza virus, but 
plasmacytoid DCs (pDCs) which make type I IFN α/β are thought to use TLR 3, 7 and 9 
[54]. Interferons are key molecules that induce DC maturation. The conventional DCs 
produce a lot of proinflammatory cytokines such as IL-6, IL-12, TNFα, IL-8 [55]. A recent 
study showed that TNFα/inducible nitric oxide synthase (iNOS) producing DCs (tipDCs) 
can be recruited into the lungs using CCR2 during early influenza virus infection and 
present antigens to virus-specific CTLs [56]. 
 
Different subsets of DCs have been identified in the lungs using characteristics such 
as anatomical distribution, surface markers and migratory patterns [57;58 ]. The 
respiratory DCs include two migratory subsets which are CD11b+ and CD103+ DCs play 
a pivotal role in the initiation of adaptive immune responses. Both DCs reside 
underneath the airway epithelium and continuously sample antigens from the airway 
lumen by extending their dendrites [59;60]. Once the DCs uptake antigens, they migrate 
into the mediastinal lymph node (MLN) through the afferent lymphatic vessels using 
CCR7, which is lymph node homing receptor. During migration the DCs become 
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activated and upregulate costimulatory molecules such as CD80 and CD86 on their 
surface [61]. The mature DCs present antigens as small peptides in the context of major 
histocompatibility complex (MHC) and elicit robust adaptive immune responses in the 
MLN and spleen [62;63].   
 
B. Cytotoxic T lymphocyte immunity 
i. Signals that lead to naïve CD8 T cell activation 
CD8 T cells are important cells for immune surveillance of the body against a variety 
of infections, because they can migrate into many different tissues where virus infections 
begin. Naïve CD8 T cells express L-selectin (CD62L), chemokine receptor 7 (CCR7) and 
leukocyte function antigen-1 (CD11a) which play different roles in the rolling, adhesion, 
and  T cell extrasvasation into the peripheral lymph nodes via HEV [64]. Naïve CD8 T 
cells circulate through secondary lymphoid organs until they meet APCs with their 
cognate antigen. Cognate antigen recognition and costimulatory signals are required for 
naïve to become effector CD8 T (Teff) cells. At this time, T cell receptor (TcR ; signal 1) 
on naïve CD8 T cells interacts with processed peptides in the context of MHC class I 
molecules and CD28 (signal 2) on CD8 T cells also interact with the costimulatory 
molecules including CD80 and CD86 on DCs [65]. In addition, a third signal such as IL-12 
is required for full differentiation and effector functions [66]. After antigen encounter, the 
naive CD8 T cells undergo the phenotypic changes to become Teff cells which migrate 
to the lungs during influenza virus infection [67]. 
 
ii. Molecules that control CTL migration into the lungs  
Antigen stimulation plays a central role in the generation of Teff and memory T cells 
which play a role in protective immunity. Once T cells become activated, they migrate 
into infected site, using many different integrins and chemokine receptors, and ultimately 
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kill infected cells by contact-dependent interactions [21]. Integrins are cell surface 
receptors that form adhesions between migrating cells and the extracellular matrix. The 
family includes 18 α subunits and 8 β subunits which pair αβ subunits [68]. Integrins play 
crucial roles in leukocyte activation, extravasation and cytotoxic killing activity. Activated 
CD8 T cells express high levels of β2-integrin lymphocyte function-associated antigen1 
(LFA-1; αLβ2 integrin) and α4 integrin very late antigen-4 (VLA-4; α4β1) [69]. LFA-1 binds 
to intercellular adhesion molecules 1 and 2 (ICAM1 and ICAM2) which are constitutively 
expressed on the vascular endothelium and in the intherstitium [70]. The intracellular 
signals by CCL19 and CCL21 increase the integrin affinity by inducing its conformational 
change [71]. VLA-4 interacts with vascular cell-adhesion molecule1 (VCAM1) and 
mucosal vascular addressin cell-adhesion molecule 1 (MADCAM-1). A previous study 
demonstranted that LFA-1 plays a role in retention of activated CD8 T cells in the lungs, 
rather than delayed the endothelial transmigration, but there is no effect on cell adhesion 
after blockade of VLA-4 [69]. When influenza specific CTLs arrive at the airways, CD11a 
is down-regulated within 40 hours, it can be re-expressed when the cells are transferred 
into other mice [72;73]. A recent study reported a mechanism by which nearly the entire 
extracellular domain of CD11a is cleaved by metalloproteinase-9 (MMP-9) from 
macrophages [74]. Since influenza virus- specific CTLs lose the ability to recirculate after 
they reach the airways [75], it is likely that they are removed by mucociliary escalator. 
The CD11alow cells in the airways are functional in proliferation, but they are impaired in 
cytolytic activity during respiratory virus infection [76;77]. However, these cells may 
contribute to protective immunity by stabilizing the interactions between CTL and the 
target cells during cytolysis using interactions between CD103 and E-cadherin which 
play a role in cytolytic function and by secretion of proinflammatory cytokines [78;79]. 
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Another study has shown that α1 integrin VLA-1 (very late antigen-1; α1β1), which 
binds to type IV collagen, is highly expressed on the influenza virus-specific CTLs that 
can be collected from the airways by bronchoalveolar lavage (BAL). This study 
demonstrated that VLA-1 expressing CD8 T cells have higher ability to secrete IFNγ, 
than influenza virus-specific CD8 T cells which lack VLA-1 expression, and are retained 
in the lungs where they provide protective immunity against secondary challenge [80;81]. 
The VLA-1+ CD8+ T cells in the lungs expressed CD69+, and CD44high but lacked CD62L , 
suggesting that they were Teff cells. 
 
Chemokine receptors are G-protein-coupled receptors which have a 7 
transmembrane structure. There are 19 distinct chemokine receptors in mammals which 
can be divided into 4 different subfamilies based on the number and disposition of 
cystein residues (CC, CXC, CX3C and XC) in near their amino termius. Chemokine 
receptors play a central role in chemotaxis and recruit T cells to inflamed sites in 
response to chemokine ligands [82]. A recent study demonstrated that CXCR3 (the 
receptor for CXCL10) plays a role in virus-specific CTL migration to the lungs during 
acute respiratory infection. However, CCR5 expression, but not CXCR3, plays a role in 
recruitment of memory CTL into the airways after secondary infection with another strain 
[83]. Furthermore, CXCR3 and CCR5 deficiency caused increase a numbers of memory 
precursor cells in the lungs and spleen, which may be due to limited access to antigen in 
the lungs which can cause activation-induced cell death [84]. 
 
iii. CTL effector function   
Cytotoxic T lymphocytes (CTLs) play a key role in eliminating influenza virus 
infected cells by inducing apoptosis through contact-dependent interactions. Therefore, 
influenza virus-specific CTLs must be recruited to the lung epithelial cells that are 
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releasing the new infectious virus. After engagement of the T cell receptors with cognate 
antigen in the context of MHC I, the CTLs secrete cytolytic granules into the 
immunological synapse. CTL can destroy more than one infected cell during sequential 
interactions with multiple cells. This killing activity does not require costimulatory signals. 
 
Infections with lymphocytic choriomeningitis virus (LCMV) and Listeria 
monocytogenes (LM) induce heterogenous populations of Teff cells which can be 
identified using different surface markers such as IL-7Rα (CD127) and killer lectin-like 
receptor G1 (KLRG1). CD127+KLRG1- antigen specific CD8 T cells is memory 
precursor effector cells (MPECs) which are characterized by high levels of CD127, CD44, 
CD62L, CD27, CD122 and Bcl-2 expression. The MPECs produce larger amounts of IL-
2, IFNγ and TNFα, than CD127- KLRG1+ CD8 T cells, after exposure to antigen [85]. 
MPECs are capable of self-renew and to proliferate in response to IL-7 and IL-15 [86]. In 
contrast KLRG1 is a marker for short-lived effector cells (SLECs) which are able to 
proliferate in response to antigen and can make cytokines such as IL-2 and IL-15, but 
they do not develop into long-lived memory CD8 T cells [87]. In addition, during acute 
infection with LCMV MPEC and SLECs have similar effector functions, including cytolytic 
activity and IFNγ production [87;88]. In addition, CD127+KLRG1+ CD8 T cells which are 
double-positive effector cells (DEPCs) revealed intermediate life span and proliferation 
compared to MPECs and SLECs [87].  
 
Others have suggested that the generation and survival of SLECs and MPECs is 
regulated by many different factors such as transcription factors, cytokines, and co-
stimulatory molecules. The transcription factors T-bet and Blimp-1 play a role in the 
development of SLECs. High levels of T-bet expression decrease IL-7Rα, but low level is 
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sufficient for IL-2/IL-15Rβ (CD122) expression [87;89;90]. In addition, IL-12 is able to 
increase T-bet expression during pathogen specific CTL differentiation [91].  
 
Two major mechanisms of CTL-mediated killing have been indentified, which are 
Ca2+ -dependent perforin/granzyme mediated apoptosis and Ca2+ -independent Fas/Fas 
ligand-mediated apoptosis [92]. A recent study demonstrated that perforin induces pores, 
which increase Ca2+ influx into the target cells. In turn granzymes undergo endocytosis 
and are released into the cytosol of the target cells [93]. There are 10 different granzymes 
in mice including granzyme A and B which are the most abundant molecules [94]. It has 
been shown that granzyme A and B play different role in CTL function. Granzyme B 
induces an apoptotic pathway by cleaving capspases-3 and -9, followed by DNA 
fragmentation [95], while granzyme A is part of a caspase independent pathway which 
induces oligosomal DNA degradation [96]. Following influenza virus infection, two 
different subsets of virus-specific CTLs can be identified based on granzyme A and B 
expression. During early infection (6dpi), there were more virus-specific CTLs that were 
producing granzyme A together with granzyme B in the lungs, than virus-specific CTLs 
which were producing granzyme B alone. However, during peak of responses (10dpi), 
virus-specific CTLs which were making granzyme B alone were outnumbered granzyme 
A/B-producing virus-specific CTLs in the lungs [97]. 
 
During antigen stimulation Teff cells upregulate Fas ligand (CD95L) which interacts 
with Fas (CD95) on the target cells. The Fas molecule is a member of the TNF receptor 
superfamily of molecules that contain an intracellular death domain to initiate caspase-
dependent apoptosis. CD95/CD95L engagement activates caspase-8 directly, which can 
cleave Bid into its active form tBid  which induces permeabilization of the mitochondria 
membrane to release cytochrome c, which in turn activates caspase 9 [98].  
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Virus-specific Teff functions, including cell-mediated cytotoxicity and 
proinflammatory cytokines, can damage the host during acute infection. To inhibit 
excessive immune responses several different mechanisms have been shown to 
shutdown the Teff responses by inducing apoptosis. Apoptosis is regulated by intrinsic 
factors that are the B cell lymphoma-2 (Bcl-2) protein family such as prosurvival (Bcl-2, 
Bcl-XL, Mcl-1, and Bcl-w) and proapoptotic molecules (Bax, Bak, Bad, Bim, Bid, and 
Puma). The prosurvival factors Bcl-2 and Bcl-XL inhibit Bim and Puma which release of 
cytochrome c from the mitochondrial membrane to activate caspase-9. The balance of 
both prosurvial and proapoptotic molecules maintains the integrity of the mitochondrial 
membrane and control apoptosis [99;100].  After viral clearance, the majority of effector 
CTLs undergoes massive programmed death, which is called the contraction phase and 
small numbers of memory CTLs survive and confer long-term protection against 
reinfection. During the contraction phase the proapoptotic molecules Bim and Puma play 
a role in induction of apoptosis [101;102]. In addition reduced amount of cytokines such as 
IL-2, IL-4, IL-7, and IL-15 promote the Teff cell death [103], since the signals from these 
cytokine are able to increase Bcl-2 and Bcl-XL levels.  
 
When activated CD8 T cells are repeatedly exposure to antigens, apoptosis is 
induced by the Fas pathway resulting in activation-induced cell death (AICD) [104]. 
However, others suggested that CD4 and CD8 T cells use different death pathways [105]. 
This study suggested that the Fas signal-induced AICD may limit in CD4 T cells, rather 
than CD8 T cells which die by other mechanisms included TGFβ. TGFβ is a pleiotrophic 
cytokine which its signal controls a  variety of cellular processes, such as cell fate 
decisions, proliferation and survivals and also acts as both proinflammatory and 
immunosuppressive cytokines [106].  A recent study demonstrated that TGFβ signaling 
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plays a role in selective induction of SLEC apoptosis during early clonal expansion by 
reducing Bcl-2 [107].   
 
iv. Heterosubtypic immunity 
Influenza viruses undergo continuous antigenic mutation which allows variants to 
escape from the antibody response. Since CTLs can recognize conserved internal 
proteins, they can provide short-term heterosubtypic immunity between different 
subtypes [108;109]. Memory CTLs kill target cells faster than naïve CD8 T cells and thus 
promote faster viral clearance than primary infection. Antigen-specific CD8 T cell 
numbers are greatly expanded after secondary challenge in the upper respiratory tract 
[110]. Adoptive transfer of NP-specific CD8 T cells into the trachea can protect mice from 
challenge of a lethal influenza virus infection [111]. After primary influenza infection, some 
Tem cells remain in the peripheral tissues and can mediate an accelerated response to 
reinfection [112;113].  
 
v. Heterogeniety of memory CD8 T cells 
After viral clearance, a large numbers of Teff cells undergo contraction phase, 
however small numbers of CD8 T cells survive and become memory T cells which 
express CD127. These memory cells can be subdivided into different subsets such as 
central memory cells (Tcm : CCR7hiCD62Lhi) and effector memory cells (Tem : 
CCR7loCD62Llo) based on the expression of the lymphoid homing receptors, CCR7 and 
CD62L [112]. Some Tem cells are preferentially found in the peripheral tissues, but Tcm 
cells are mainly located in the secondary lymphoid organs. Compare to Tcm cells, Tem 
cells mediate rapid cytotoxic activity after encounter antigen stimulation [112;113].  
 
Recent studies have demonstrated the third subsets of memory T cells which are 
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tissue-resident memory (Trm) CD8 T cells in peripheral tissues such as the skin, gut, 
salivary gland, lung and brain in different infectious models [80;114-118]. Most Trm cells 
maintain an activated phenotype similar to Tem cells. In addition Trm cells express 
CD69 and CD103. These Trm cells are less proliferative, than Tcm cells, and poorly 
replenished from the circulation. In addition, there is evidence that some Trm are able to 
making cytokines after in vitro stimulation. For example, Trm cells in the lungs also have 
the ability to produce cytokines including TNFα, IFNγ, IL-4, IL-13, and IL-17 in the 
presence of heat killed influenza virus pulsed APCs [115]. In addition, Trm cells from the 
brain or the salivary glands are able to produce granzyme B and IFNγ, respectively 
[116;118]. These data suggest that Trm cells exist as long-lived memory pools and mediate 
protective immune responses during local infections [116;119;120].  
 
C. CD4 T cell responses 
It has been shown that activation of CD4 T cells require cognate antigen stimulation 
by interacting peptides in the context of MHCII molecules presented by antigen 
presenting cells (APCs) in the draining lymph nodes (DLNs) [121]. The activated CD4 T 
cells undergo clonal expansion and differentiate into distinct subsets of Teff cells in the 
presence of different cytokines. When naïve CD4 T cells differentiate in the presence of 
IL-4, these cells become T helper 2 (Th2) cells which produce IL-4, IL-5, and IL-13. 
These Th2 cytokines stimulate B cells to produce IgG1 and IgE antibodies [122]. However, 
in the presence of IL-12 and IFNγ naïve CD4 T cells differentiate into Th1 cells which 
can mediate cellular immunity [123].  
 
Previously, others demonstrated that Th1 cells were more effective than Th2 cells in 
protection against a lethal dose of influenza virus infection, as demonstrated by adoptive 
transfer of either Th1 or Th2 cells isolated from influenza virus-infected mice [124;125]. 
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Some HA-specific CD4 T cells that are recovered from the BAL and lungs are capable of 
making high levels of Th1 cytokines IFNγ and TNFα ex vivo, but Th2 cytokines such as 
IL-4 are undetectable [126]. In addition, previous study demonstrated that CD4 T cells 
acquired perforin-mediated cytotoxicity  and increased B cell responses which produce 
neutralizing antibodies during influenza virus infection [127]. 
 
However, influenza virus-specific CD4 T cells undergo more rapid contraction phase 
in the lung parenchyma and the airways than influenza virus-specific CD8 T cells [128]. 
Therefore, smaller numbers of virus-specific CD4 T cells persist in the lungs, compared 
to virus-specific CD8 T cells, but there was no difference in spleen and lymph nodes. 
After secondary challenge virus-specific memory CD4 T cells are greatly expanded in 
the upper respiratory tract [110]. These memory CD4 T cells have a role in innate 
immunity because they are able to produce large amounts of cytokines including IFNγ, 
IL-12 and IL-6 within 48 hours after influenza virus infection [129] .In addition, memory 
CD4 cells also promote the maturation of antigen presenting cells by production of 
proinflammatory cytokines such as IL-2 [130], which further enhances virus-specific CD8 
T cell responses such as CTL activation and trafficking. Therefore, CD4 helper cells play 
an important role in regulating heterosubtypic immunity. 
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CHAPTER II: 
 
ANIMALS, MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
18
 
 
Mice  
C57BL/6 and congenic CD45.1+ mice were purchased from Charles River 
through the NCI animal program. The CD69KO [131], CD103KO [132], dnTGFβRII [133], 
GFP+2.3 [134] and Ubiquitin-GFP+ mice [135] were generously provided by other 
investigators and cross-bred with F5 and OTI TcR transgenic mice lines at the University 
of Connecticut Health Center. All experiments were performed in accordance with 
regulations by the American Association for Accreditation of Laboratory Animal Care, as 
well as federal and state agencies.  
 
Bone marrow chimeras  
Between 4 - 6 weeks of age female mice were lethally irradiated (1000 rads) and 
one day later treated with 200g anti-CD8 antibodies (Clone 2.43) to deplete remaining 
host-derived CD8 T cells. Bone marrow cells from dnTGFβRII+ and wild type mice were 
mixed at different ratios (total 107) before transfer to lethally irradiated C57BL/6 
recipients. Congenic CD45.1 and CD45.2 markers were used distinguish the mutant and 
wild CD8 T cells. Recipient mice were maintained for 6 - 8 weeks before viral infection.  
 
Viruses and infections 
Mice were anesthetized by i.p. injection with 250 – 300 µl (1.6 g/ml avertin) 
(2,2,2-tribromoethanol) and received either 600 50% egg infectious doses (EID50) E61-
13-H17 influenza virus, or 106 EID50 X31-OVA [136], or 600 EID50 HKx31, or 103 pfu WSN-
OVAI [67] intranasally (i.n.). The fertilized chicken eggs were purchased from the Charles 
River Laboratory and virus stocks were grown, titered and stored as described 
previously [137].  
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Transfer experiments  
Spleens and peripheral lymph nodes were dissociated to form single cell 
suspensions and depleted of red blood cells. For in vivo competition assays recipient 
animals received a total of 106 mixed lymphocytes by tail vein injection. Alternatively, 
lymphocytes were labeled with 1μM carboxy fluorescein diacetate succinimidyl ester 
(CFSE)-dye at 37°C for 10mins and 2x105 cells were transferred to the recipients [138].  
 
Sample preparation for tetramer analysis 
Non-adherent cells were collected from the lungs by lavage 5 times in Hank's 
balanced saline solution (HBSS).  Mice were exsanguinated. Ground glass microscope 
slides were used to make cell suspensions from spleens and peripheral lymph nodes. 
Red blood cells were lysed with ammonium chloride and lymphocytes were filtered 
through cell strainers. Lymphocytes were released from chopped lung tissue by 
digestion with 150 U/ml collagenase (Life Technologies, Rockville, MD) in RPMI, 1 mM 
MgCl2, 1 mM CaCl2 and 5% FCS, at 37°C for 90 mins. Cells were pushed through 
strainers and spun on 44/67% Percoll gradients at 400g for 20 mins. Lymphocytes were 
washed with PBS. Washed lymphocytes were stained with tetramers that are specific for 
the influenza virus NP366-374/Db and PA324-333/Db epitopes as described previously [139;140]. 
Lymphocytes were stained with APC-conjugated tetramers and anti-CD8 (clone 53.6.72) 
for 1 h. at room temperature. For flow cytometer analysis all other markers were stained 
at 4°C using mAb specific for CD45.1, CD45.2, CD44, CD69, CD103, CD127, PD-1, 
KLRG1 and CD62L (eBioscience or BD Pharmingen, San Diego CA). The samples were 
analyzed on a Becton-Dickinson FACSCalibur or LSR-II flow cytometer and analyzed 
using Flowjo software (Tree Star Inc.). Dying cells were identified using a fluorescent 
dye that interacts with free amines (Invitrogen). To block antigen presentation, mice 
were treated twice with 25D1.16 or control antibodies, 20dpi (100ug i.n. plus 400ug i.v.) 
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and 23dpi (250ug i.v.). 
 
Confocal microscopy 
Visualize transferred OTI cells in situ fragments of lung tissues were fixed in 2% 
(1% used for GFP+ cells) paraformaldehyde (PFA) for 20 mins at 4°C. Lung tissue was 
stained for 6hr at 4°C with the antibodies, including Ep-CAM, CD31, CD45.1 and anti-
GFP antibodies (eBioscience or BD Pharmingen, San Diego CA). The washed tissues 
were mounted on slides using Shandon Immu-Mount or 50% glycerol in 2x PBS 5mM 
MgCl2 for GFP+ cells. Images were collected using a Zeiss LSM-780-Meta confocal 
microscope with an automated Axiovert 100M platform with xyz control. Image data was 
analyzed using Metamorph® software (Universal Imaging Corp, Downingtown, PA) and 
Imaris® Suite (Bitplane Inc). Colocalization and isosurfiacing were applied to multiple 
images using Imaris imaging software. 
 
Intracellular cytokine staining analysis 
Lymphocytes were enriched from the Spleen and lungs. For in vitro peptide 
stimulation, lymphocytes (total 5x106 cells/well) were cultured in the presence of NP or 
PA peptide (1μg/ml) with Brefeldin A (BFA) (20μg/ml) for 5 hrs at 37°C incubator. 
Stimulated lymphocytes were stained with antibodies, including CD45.1, CD45.2 and 
CD8 and fixed with 2% PFA on ice. Lymphocytes were permeabilized with 0.1% saponin 
and stained for cytokines, including IFNγ and TNFα  
 
Statistics 
Unless otherwise stated, all experiments were repeated at least twice using a 
minimum of 3 animals per group. Statistical significance was determined using an 
unpaired two-tailed Student T test. The comparisons that were used to generate P 
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values are indicated by horizontal lines (* P <0.05, ** P <0.01, *** P <0.001). 
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CHAPTER III.  
 
THE INFLUENCE OF TGFβ ON CTL RESPONSES IN THE LUNGS 
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ABSTRACT 
 
Large percentages of the virus-specific CD8 T cells that express CD103 stay in the 
lungs during the recovery from influenza virus infection. Since TGFβ is known to induce 
CD103 expression on CD8 T cells in other models, we crossed F5 TcR transgenic mice 
with dnTGFβRII mice that express a dominant negative form of the TGFβRII 
(dnTGFβRII) to investigate whether TGFβ induced CD103 expression in the lungs. 
When I transferred the F5-WT and F5-dnTGFβRII+ cells into the same recipient mice, I 
found that very few F5-dnTGFβRII+ cells expressed CD103 when the TGFβ signaling 
pathways were blocked. These data showed that TGFβ signals are required for CD8 T 
cells to express CD103 in the lungs. 
 
To determine how TGFβ influences the other virus-specific CTL responses in the 
lungs, we made chimeric mice with mixed bone marrow cells from the dnTGFβRII and 
wild type animals. When the TGFβ signals were blocked, there were dramatically 
increased numbers of KLRG1+ virus-specific Teff cells in all tissues 10dpi, including the 
lungs. Since virus-specific CTLs can damage the lungs, I tested the ability of the CD8 T 
cells from wild type and dnTGFβRII+ chimeric mice to make proinflammatory cytokines. 
After in vitro stimulation larger numbers of dnTGFβRII+ CD8 T cells produced IFNγ 
alone, or IFNγ together with TNFα, as compared to the wild type CD8 T cells. 
Histological analysis also showed that there were more extensive areas of inflammation 
in the dnTGFβRII chimeric mice, than in the WT B6 chimeric mice. When I used confocal 
microscopy to compare the distribution of KLRG1+ and KLRG1- virus-specific CD8 T 
cells in the lungs, the majority of OTI-dnTGFβRII+ cells which expressed KLRG1 were 
located in the tissues around the alveoli 10dpi, but there were very few mutant cells in 
the lumen of the airways. At later time points some OTI-WT cells which expressed 
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CD103 were located in the airways. These studies showed that TGFβ signaling 
selectively reduced the numbers of KLRG1+ virus-specific Teff cells in the lungs, while 
upregulated CD103 expression on many surviving virus-specific CTLs in the airways.  
 
Since CD103 is an adhesion molecule which can promote interactions with epithelial 
cells that express E-cadherin, I used transfer experiments to directly investigate whether 
CD103 expression helps retain virus-specific CD8 T cells in the lungs. After OTI TcR 
transgenic mice were crossed with CD103KO mice, I transferred equal numbers of OTI-
WT together with OTI-CD103KO cells to the recipient mice 2 days before infection with 
WSN-OVAI virus. During the peak of the CTL response I found approximately equal 
ratios of CD103KO and wild type CD8 T cells in all tissues. As the infection progressed 
the ratios in the lungs changed and there were less OTI-CD103KO than OTI-WT cells. In 
addition, confocal microscopy showed that both WT and CD103KO cells were distributed 
throughout the lungs during the peak of CTL response. Later in the infection the 
percentages changed and there were less of CD103KO, than wild type, cells in the 
airways.  
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INTRODUCTION 
 
Naïve CD8 T cells expand and differentiate into Teff cells after they encounter their 
cognate antigen on APCs in the draining lymph node. These antigen-activated CTLs 
must then migrate to the sites of viral replication to promote viral clearance. The homing 
receptors that are required for efficient CTL migration to the infected tissues include 
integrins which promote adhesive interactions between T cells and other cell types. 
 
Integrins are a family of transmembrane proteins, which play a role in adhesive 
interactions that are important for T cell recirculation, migration and recognition of foreign 
antigens [68]. Several studies have demonstrated that specific integrins are involved in 
CTL migration to the mucosal tissues. For example, α4β7 integrin interacts with mucosal 
addressin cell adhesion molecule-1 (MadCAM-1) and plays a role in mediating the entry 
of T cells into the intestine [141;142]. The expression of α4β7 is down regulated and αEβ7 
(CD103) is upregulated when pathogen-specific CD8 T cells arrive in the intestinal 
mucosa where TGFβ is made [143]. Another integrin known as the lymphocyte function-
associated antigen 1 (LFA-1 or αLβ2; CD11a/CD18) also plays a role in CTL migration 
to peripheral tissues including the lungs, by promoting interactions with intracellular 
adhesion molecule-1 (ICAM-1) on endothelial cells. These interactions are regulated by 
chemokines CCL12 and CXCL21 which induce a conformation change in the integrin 
which increases its affinity for ICAM-1ligand [144]. In addition, the very late antigen-1 
(VLA-1; α1β1) is a collagen receptor which promotes retention of the antigen-specific 
CTL in the lungs and plays a role in protective immunity against secondary infection [21]. 
In this study I will focus on CD103, since many virus-specific CD8 T cells express 
CD103 in the airways after influenza virus infection [145;146]. In addition, since TGFβ 
signaling is required for CD103 expression on CD8 T cells in other tissues including the 
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kidney [147], I also investigated the role of TGFβ in regulating the T cell response. Since 
we believe that virus-specific memory CD8 T cells in the lungs play a key role in 
heterosubtypic immunity, it is important to understand the role of TGFβ signaling in the 
generation of antigen-specific tissue resident memory (Trm) CD8 T cells [148]. 
 
During CD8 T cell differentiation, antigen-specific effector CD8 T cells (Teff) can be 
subdivided into memory precursor and short-lived Teff cells based on CD127 (IL-7Rα) 
and KLRG1 expression. The memory precursor Teff cells (MPECs) are CD127+KLRG1- 
CD8 T cells which have the capacity for robust proliferation and long-term survival in the 
absence of antigen [85]. In contrast, CD127- KLRG1+ CD8 T cells are short-lived Teff 
cells (SLECs) that are impaired in proliferation, but are capable of immediate effector 
functions [149]. A third subset of Trm cells has recently been identified in peripheral 
tissues, including the skin, brain, gut and lungs [114-116;119 ]. These Trm cells maintain an 
activated phenotype by expressing molecules such as CD69 as well as CD103 which is 
regulated by TGFβ. A recent study demonstrated that TGFβ signaling also reduces the 
survival of KLRG1+ virus-specific CTLs after LCMV infection [107], it is largely unknown 
how TGFβ signaling impacts virus-specific CTL responses in the lungs during influenza 
virus infection.  
 
In this chapter, I have used mice that express a dominant-negative form of the 
human transforming growth factor beta receptor II (dnTGFβRII) under control of the CD4 
promoter without the CD8 silencer [150], to understand how TGFβ signaling changes the 
responses of influenza virus-specific CD8 T cells. I also used CD103-deficient mice [132] 
to directly determine how CD103 expression on antigen-specific CTLs impacts their 
migration and/or retention in the lungs. My data demonstrate that large numbers of 
KLRG1+virus-specific CTL accumulate in the lungs in the absence of TGFβ signaling. 
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Furthermore, TGFβ is required for CD103 expression on KLRG1- virus-specific CTLs in 
the airways during late stage of the infection. 
  
The data that are presented in this chapter are divided between three specific aims. 
Each aim addresses a specific question about the way that environmental factors 
(TGFβ) influence the numbers and phenotype of virus-specific CD8 T cells in the lungs. 
The questions are outlined below. 
 
Aim 1.1: Does TGFβ signaling influence the numbers of virus-specific CTL in the 
lungs? 
Aim 1.2: Is TGFβ signaling required for CD103 expression on virus-specific CTL in 
the lungs? 
Aim 1.3: How does CD103 change the distribution of virus-specific CTLs inside 
the lungs? 
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RESULTS 
Aim 1.1: Does TGFβ signaling influence the numbers of virus-specific CTL in the 
lungs? 
 
Blockade of TGFβ signaling increases the numbers of KLRG1+ virus-specific CTLs in 
the lungs. 
TGFβ is a pleiotropic cytokine which can influence cell fate decisions, 
proliferation and survival [106]. A recent study demonstrated that TGFβ signaling reduced 
the survival of KLRG1+ virus-specific CTLs during early clonal expansion [107], however, 
it is largely unknown how TGF β signaling influences the CTL response in the lungs 
during influenza virus infection. To determine whether TGFβ signaling influenced the 
numbers of virus-specific CTL in the lungs, I performed collaborative experiments with 
other members of our laboratory. C57BL6 mice were irradiated and bone marrow cells 
(5x106) from B6 and dnTGFβRII mice (mixed at 1:1) were transferred into irradiated B6 
mice. After 8 weeks the reconstituted mice were infected with the HKx31 virus and 
CD45.1/CD45.2 congenic markers were used to compare the numbers of NP- and PA-
specific WT and dnTGFβRII+ CD8 T cells by MHCI tetramer analysis. I found larger 
numbers of NP- and PA-specific CD8 T cells which expressed KLRG1 in the BAL, lungs 
and spleen 10dpi when the dnTGFβRII+ was present (Figure 3-1B and 3-1C). High 
numbers of tetramer-specific dnTGFβRII+ CD8 T cells which expressed KLRG1 were 
also found in the lungs and spleen 20dpi, but there were very few CD8 T cells in the BAL 
(Figure 3-1B and 3-1C). These data suggest that TGFβ plays a role in reducing the 
numbers of KLRG1+ virus-specific Teff cells in the lungs during acute viral infection, and 
further suggest that CTLs which lack CD103 are not efficiently retained in the airways.  
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TGFβ induces CD103 expression on KLRG1- virus-specific CTLs in the lungs. 
The data suggest that TGFβ signaling induces different responses from KLRG1- 
and KLRG1+ virus-specific CTL (Figure 3-1). To investigate how TGFβ signals impact 
CD103 expression on the KLRG1- and KLRG1+ subsets of virus-specific CTLs in the 
lungs, we subdivided the virus-specific CTL into two subsets using KLRG1 antibodies 
shown in Figure 3-1. Each subset of KLRG1+ and KLRG1- of virus-specific CD8 T cells 
was then further analyzed for CD69 and/CD103 expression (Figure 3-2). We found that 
CD103 was only expressed on KLRG1- NP-specific WT CD8 T cells in the lungs10dpi, 
but was not present on KLRG1+ cells. Small numbers of KLRG1- CD8 T cells also 
expressed CD103 in the lungs which suggested that dnTGFβRII did not outcompete the 
endogenous TGFβRII on some CD8 T cells. In addition, there were some KLRG1- NP-
specific WT CD8 T cells expressed CD69 alone or CD103 together with CD69 in the 
lungs, but small numbers of KLRG1+ cells that expressed CD69 alone. However, there 
were similar percentages of NP-specific dnTGFβRII+ CD8 T cells which expressed 
CD69 alone between KLRG1+ and KLRG1- subsets in the lungs. By 20dpi we found 
some KLRG1- NP-specific WT CD8 T cells which expressed CD69 alone or CD103 
together with CD69 in the lungs, but small numbers of the KLRG1+ cells expressed only 
CD69. In contrast, small numbers of KLRG1+ and KLRG1- subsets expressed CD69 
when TGFβ was blocked. This suggests that TGFβ selectively induces CD103 
expression on KLRG1- CTL in the wild type mice during influenza virus infection. 
 
Virus-specific CTLs produce cytokines in the absence of TGFβ signaling. 
Tumor models show that TGFβ can be secreted from tumor cells and prevents 
CTL from making cytokines without causing cell death [151]. To investigate whether TGFβ 
signaling influenced the effector function of virus-specific CTLs during influenza virus 
infection, I performed intracellular cytokine staining after cell culture in the presence of 
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synthetic NP31 and PA peptides. Bone marrow cells from either B6 WT or dnTGFβRII 
mice were transferred into the separate groups of irradiated B6 mice. CD8 depletion 
antibodies were administrated to the recipient mice one day after the bone marrow 
transfers to deplete residual host CD8 T cells. The recipient animals were infected with 
HKx31 virus ~8 weeks after reconstitution. Lymphocytes were recovered from lungs and 
spleens and the cells were cultured (5x106 /well) in the presence of 1μg NP or PA 
peptides. The cells were fixed and analyzed for IFNγ and TNFα production 10 and 21dpi 
(Figure 3-3). These data showed that larger numbers of dnTGFβRII+ CD8 T cells made 
IFNγ alone, or IFNγ together with TNFα, in response to peptide stimulation 10dpi, as 
compared to the WT CD8 T cells (Figure 3-3B). I also found larger numbers of 
dnTGFβRII+ than WT CD8 T cells that expressed IFNγ alone, or IFNγ together with 
TNFα, in the lungs and spleen after stimulation with PA peptides 20dpi, than the WT 
CD8 T cells. However there was no significantly different between the two groups when 
NP peptides were used for stimulation (Figure 3-3C). These data indicate that TGFβ 
signaling reduces the numbers of IFNγ-producing CTLs in the lungs after influenza virus 
infection. 
 
Lack of TGFβ signaling results in increased numbers of infiltrating leukocytes in the 
lungs. 
Since IFNγ and TNFα can cause severe immunopathology [152;153] and I found a 
lot of cells that were capable of making these proinflammatory cytokines in the lungs 
when TGFβ signals were blocked, I used histological analysis to determine how TGFβ 
influenced the local inflammatory response in the lungs. Bone marrow cells from B6 WT 
or dnTGFβRII mice were transferred to irradiated B6 mice, which were infected with 
HKx31 virus ~8 weeks later. The lungs were harvested from groups of 3 mice 10dpi and 
infused with paraformaldehyde (PFA) and cut into sections for staining with hematoxylin 
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and eosin (H&E). These studies showed large numbers of infiltrating lymphocytes in the 
lungs of both groups of animals 10dpi, however there were more extensive areas of 
inflamed lung when the mice were made with bone marrow cells from dnTGFβRRII+ 
mice (Figure 3-4). These data indicate that TGFβ signaling plays a role in reducing 
inflammatory immune responses in the lungs after influenza virus infection. 
 
Aim 1.2. Is TGFβ signaling required for CD103 expression on virus-specific CTL in 
the lungs? 
 
TGFβ signaling induces CD103 expression on virus-specific CD8 T cell in the lungs. 
Since TGFβ is required for CD103 expression on CD8 T cells in other tissues [147], 
I investigated whether TGFβ signaling was required for CD103 expression on influenza 
virus-specific Teff cells in the lungs. We crossed F5 TcR transgenic mice with 
dnTGFβRII mice [150], and equal numbers of F5-WT and F5-dnTGFβRII+ cells (total106) 
were transferred to the recipient mice one day before E61-13-H17 infection (Figure 3-5). 
The CD45.1/CD45.2 congenic markers were used to compare the ratios of transferred 
cells in different tissues. Since human DNA was used to make the dnTGFβRII construct, 
the transferred dnTGFβRII+ cells are rejected from the host between 10-20dpi [154], so I 
was only able to track the transferred F5-dnTGFβRII+ cells until 9 dpi.  
 
In this experiment I detected larger percentages of F5-dnTGFβRII+ cells in the 
MLN and spleen, compared to F5-WT cells (Figure 3-5B). In addition, there were higher 
ratios of F5 WT than F5-dnTGFβRII+ cells in the airways and lungs. I found dramatically 
reduced CD103 expression on F5-dnTGFβRII+ cells in the lungs 9dpi, compared to the 
F5-WT cells as shown by overlaid histograms. Since the mutant dnTGFβRII must 
compete with the endogenous TGFβRII on CD8 T cells, small percentages of F5-
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dnTGFβRII+ cells expressed CD103 in the lungs 9dpi, which suggested that the 
mutation may be slightly leaky. These data indicate that TGFβ is required for CD103 
expression on virus-specific CTLs in the lungs after influenza virus infection.  
 
Aim 1.3: How does TGFβ signaling change the distribution of virus-specific CTLs 
inside the lungs? 
 
KLRG1+ cells exhibits different location in the lungs during the recovery phase.  
The flow cytometry data showed large numbers of KLRG1+ cells in the lungs 
when the dnTGFβRII was expressed 10dpi (Figure 3-1B), but there were very few 
KLRG1+ cells in the BAL 20dpi (Figure 3-1C). I compared the distribution of KLRG1- and 
KLRG1+virus-specific CD8 T cells inside the lungs. To prevent the dnTGFβRII + cells 
from being rejected, I made chimeric recipients using CD45.2+ bone marrow cells from 
WT B6 and dnTGFβRII mice (mixed10:1 ratio). After ~8 weeks reconstitution I 
transferred either CD45.1 OTI-WT (103) or CD45.1OTI-dnTGFβRII+ (103) cells to 
separate groups of chimeric mice and two days later infected them with the WSN-OVAI 
virus (Figure 3-6A). The CD45.1 congenic marker was used to tract the transferred OTI 
cells during imaging. To stain the endothelial cells in the blood vessels, I gave CD31 
antibody by intravenous injection 15mins before the lungs were harvested. Fragments of 
lung tissue were fixed with PFA and further stained with CD45.1, KLRG1 and Ep-CAM 
antibodies. The outer boundary of airway wall was identified with the Ep-CAM antibodies 
(red), as indicated by the white dashed lines. The lung tissues were analyzed by 
confocal microscopy (Figure 3-6B). 
 
The results showed that large numbers of KLRG1+ OTI-dnTGFβRII+ cells were 
located around the alveoli 10dpi, (Figure 3-6B and 3-6C). In contrast, many KLRG1- 
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OTI-WT cells were located in the walls of the airways (Figure 3-6D and 3-6E). The 
numbers of KLRG1+OTI-WT cells declined in the lungs 20dpi, but substantial numbers 
of KLRG1+OTI-dnTGFβRII+cells were still found around the alveoli 20dpi. Interestingly, 
most KLRG1- OTI-WT cells which expressed CD103 were embedded in the airways at 
the late time points (Figure 3-6F). These data suggest that TGFβ induced expression of 
CD103 on virus-specific CD8 T cells and thus helps remain the cells in the lungs during 
influenza virus infection. 
 
CD103 expression plays role in retention of CD8 T cells in the lungs. 
Previous studies have implicated CD103 for a role in CTL migration or retention 
in mucosal tissues [132;147]. To directly determine whether CD103 plays a similar role in 
the lungs, we generated OTI-CD103KO mice by crossing OTI mice with CD103KO mice 
[132]. I adoptively transferred equal numbers of OTI-WT and OTI-CD103KO (total106) in 
the same recipients two days before WSN-OVAI infection. I used the CD45.1/CD45.2 
congenic markers to compare the ratios of OTI-WT and OTI-CD103KO cells in different 
tissues at 10, 20 and 35dpi (Figure 3-7A). 
 
This experiment showed almost equal ratios of OTI-WT and OTI-CD103KO cells 
in all tissues including the lungs, spleen and MLN 10dpi, which indicates that CD103 did 
not have a major impact on virus-specific CTL migration to the lungs during the peak of 
the CTL response (Figure 3-7B). At later time points (20-35dpi) there were higher ratios 
of OTI-WT cells (~ 60%), as compared to OTI-CD103KO cells (~ 40%) in the BAL and 
lung parenchyma. In this experiment I found that some CD103KO virus-specific CD8 T 
cells accumulated in the spleen during the late stage of infection, however, other 
experiments did not show the same pattern. This suggests that CD103 deficiency does 
not influence migration to the lungs during the Teff response, but leads to impaired 
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retention of virus-specific Teff cells in the lungs during the late stage of the infection. By 
10dpi the transferred cells expressed similar levels of CD69, but there was a selective 
loss of CD69+ CTL at later time points when CD103 was not expressed. These data 
indicate that CD103 helps retain virus-specific CTLs in the lungs during late antigen 
presentation. 
 
We also generated F5-CD103KO mice by crossing F5 TcR transgenic mice with 
CD103KO mice and I transferred equal numbers of F5-WT and F5-CD103KO cells (total 
106) to the recipient mice two days before infection with E61-13-H17. The CD45.1/ 
CD45.2 congenic markers were used to compare the ratios of mutant and WT cells in 
different tissues. I found equal ratios of F5-WT and F5-CD103KO cells in the lungs 10dpi, 
but the F5-WT cells (~ 70%) outnumbered the F5-CD103KO cells (~ 30%) 20 and 30dpi 
(Figure 3-7C). These data also support the idea that CD103 is required for prolonged 
retention of F5-WT cells in the lungs. 
 
CD103 expression changes the distribution of virus-specific CTL inside the lungs. 
Since my data show that CD103 expression increases the numbers of virus-specific 
CTL in the airways during the late stage of the infection, I used scanning confocal 
microscopy to investigate whether CD103-deficiency changed the distribution of virus-
specific CTLs in different anatomical compartments within the lungs. To produce OTI 
cells that could be visualized after transfer, we crossed OTI-WT and OTI-CD103KO mice 
with Ubquitin-GFP mice which express green fluorescent protein (GFP) in all cell types 
[135] . I used GFP+ 2.3 mice as recipients since they express GFP in the bone marrow 
and will tolerate the GFP+ T cells [134]. I transferred equal numbers of GFP+ OTI-
CD103KO (103) and CD45.1+ OTI-WT (103) cells into GFP+ 2.3 mice two days before 
infection with WSN-OVAI virus. Confocal microscopy was used to compare the 
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distribution of CD45.1+ and GFP+ cells in the lungs at different time points (Figure 3-8A). 
By 10dpi I detected no difference in the location or ratios of OTI-WT and OTI-CD103KO 
cells in the lungs by microscopy and flow cytometry analyses (Figure 3-8B). By 19 and 
30dpi I compared the ratios by counting cell numbers at the airways and the lung 
parenchyma from several images. There were less OTI-CD103KO cells than OTI-WT 
cells in the airways and lung parenchyma 19dpi (Figure 3-8C). By 30dpi I obtained 
significantly reduced numbers of OTI-CD103KO cells, as compared to OTI-WT cells in 
the airways, but there was no difference in the lung parenchyma (Figure 3-8D). These 
data indicate that CD103 helps retain virus-specific CTL in the lung airways where E-
cadherin is highly expressed during the recovery phase of the infection. 
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DISCUSSION 
 
In this chapter I have shown that some CD103+ virus-specific CD8 T cells are 
located in the airways during late antigen presentation and that TGFβ induces CD103 
expression on these virus-specific CTL. TGFβ is a pleiotrophic cytokine which regulates 
many cellular processes including T cell proliferation and survival [106]. My data show 
that the numbers of KLRG1+ virus-specific Teff cells were greatly increased when TGFβ 
signaling was blocked (Figure 3-1). This is consistent with a previous study which 
showed that TGFβ signaling over-rides IL-15 induced expression of the prosurvival 
molecule Bcl-2 (B-cell lymphoma 2) and selectively induces apoptosis of short-lived Teff 
cells during clonal expansion in LCMV infected mice [107].  
 
In tumor models TGFβ is secreted from the tumor cells and directly acts on CTLs to 
inhibit production of cytokines and other effector molecules such as IFNγ, granzyme A 
and B [151], suggesting that TGFβ signals can inactivate some CTL without killing them. 
My data also showed that a blockade in the TGFβ signaling pathway increased the 
numbers of virus-specific Teff cells that were capable of making IFNγ alone, or IFNγ 
together with TNFα (Figure 3-3). In this model, my data indicate that the decrease in 
cytokine-producing CTL was due to apoptosis of the virus-specific Teff cells, as 
measured using a fluorescent dye that crosses the membranes of dead cells and binds 
to free amines in the cytoplasm. In addition, my data show that the peak of the CTL 
response (10dpi) corresponds with large numbers of infiltrating leukocytes in the lungs in 
the absence of TGFβ signaling (Figure 3-4). Although this implies that large numbers of 
cytokine-producing Teff cells have the potential to cause severe lung damage, we did 
not see any dead animals after infection with the HKx31 virus, which is a mildly 
pathogenic strain. Other studies have shown that large quantities of proinflammatory 
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cytokines can cause high mortality rates in humans during infections with more 
pathogenic strains, including H5N1viruses, as well as the H1N1 strain that was 
responsible for the 1918 pandemic [152;155-157]. During these infections a cytokine storm 
contributed to several disease symptoms including fever, viral pneumonia, respiratory 
failure and lymphopenia [158;159]. My data suggest that TGFβ signaling down regulates 
the inflammatory response by reducing the numbers of virus-specific Teff cells in the 
lungs during infection with a less pathogenic strain. 
 
Large amounts of TGFβ are produced in the lungs after infection with some 
influenza and other respiratory viruses [160]. TGFβ can be expressed by a variety of cells 
including fibroblasts and stromal cells, macrophages, T cells, dendritic cells and mouse 
tracheal epithelial cells [106;161]. The TGFβ is secreted as an inactivated homodimeric 
proprotein known as the latency-associated polypeptide (LAP) which must be activated 
to release a short peptide that is responsible for receptor binding [162] . The cleavage 
reaction can be induced by a variety of molecules with protease activity, including 
thrombospondin-1 (TSP-1) which binds to N-terminal region of LAP and induces a 
conformational change which makes active TGFβ1 accessible its receptor. The integrin 
αvβ6, which is expressed on lung epithelial cells, can also bind to a specific arginine-
glycine-aspartic acid (RGD) sequence in the LAP and activate TGFβ1 [163]. Alternatively 
the influenza virus neuraminidase protein (NA) has enzymatic activity and can cleave 
LAT-TGFβ into its active form, although the efficiency of the cleavage reaction varies 
between different strains [164].  Since the active peptide contains a hydrophobic domain, 
it has a very short half-life in vivo and must be quantified using immunoblot analysis [165]. 
 
KLRG1 is a cell surface molecule that can inhibit virus-specific Teff function. This 
molecule belongs to the C-type lectin-like superfamily and contains an immunoreceptor 
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tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. It has been shown that 
E-cadherin is a ligand for KLRG1 and their interaction recruits SH2 (Src homology 2)-
containing inositol phosphatase-1 (SHIP-1) that acts as a negative regulator for T cell 
proliferation [166;167]. My data show that large numbers of KLRG1+ virus-specific Teff 
cells accumulate in the lungs 10dpi when TGFβ signaling is blocked (Figure 3-6). Since 
any surviving KLRG1+ virus-specific Teff cells do not express CD103, they may interact 
with lung epithelial cells which express E-cadherin.  
 
Interestingly, the engagement of KLRG1 with E-cadherin, together with the 
interaction between CD3/TCR:MHCI complex, inhibits the nuclear factor of activated T-
cells (NFAT) pathway that plays a role in expression of cytokines and cell surface 
molecules including IL-2, TNFα and Fas ligand (CD94L) [168]. In addition, cross-linking of 
KLRG1 with monoclonal antibodies decreases IFNγ production and cytolytic function in 
NK cells [169]. Therefore, these data suggest that the interaction between E-cadherin and 
KLRG1 may inhibit excessive virus-specific Teff function when TGFβ is not present in 
the lungs and thus provide an alternative pathway to decrease Teff cell-mediated 
inflammation 10dpi. 
 
A recent study revealed different distributions of KLRG1- and KLRG1+ subsets of 
pathogen-specific Teff cells in the secondary lymphoid organs during acute LCMV 
infection [170]. The KLRG1+ Teff cells preferentially accumulated in the red pulp of spleen, 
while the KLRG1- Teff cells, which expressed the CCR7 homing receptor, were found in 
the B cell zone and white pulp. However, the distribution of these two subsets of virus-
specific Teff cells in the peripheral tissues is not known. My confocal microscopy 
analysis showed that many KLRG1+ virus-specific Teff cells were located around the 
alveoli10dpi with WSN-OVAI virus (Figure 3-6B and 3-6C). Late after infection some 
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KLRG1- virus-specific Teff cells which expressed CD103 were located in the airways 
(Figure 3-6F). These data indicate that CD103 expression changes the distribution of the 
KLRG1- subset of virus-specific Teff cells in the lungs.  
 
My data supported the idea that TGFβ-induced expression of CD103 is required for 
retention of newly activated virus-specific CTL in the lungs during the recovery phase of 
the infection (Figure 3-7B). Thus, virus-specific Teff cells which lack CD103 expression 
are able to migrate into the lungs during acute infection, but they are inefficiently 
retained in the airways during the recovery phase. These data are consistent with 
previous finding that CD103 deficiency induced less accumulation host-specific Teff cells 
in the intestinal epithelium during the graft-versus-disease (GVHD) which is also a 
mucosal site [147]. 
 
Several studies have shown that Teff-like Trm cells persist in the peripheral tissues 
such as skin, salivary gland, lung and small intestine after local infections, where they 
express CD103 [80;114-118]. Some of these studies suggested that local antigen stimulation 
was required for induction and maintenance of CD103 on Trm cells in the brain and 
lungs [115;116;171]. These Trm cells require CD103 expression to retain in the brain and the 
lungs [116;171]. Previously, members of our laboratory performed parabiosis experiments 
to follow CTL migration in the blood stream. This study showed that some virus-specific 
CTLs which expressed CD69 together with CD103 stayed in the lungs during the late 
stage of the infection [145]. This supports the idea that CD103 on virus-specific CTLs is 
maintained by local antigen stimulation in the lungs. In contrast, others demonstrated 
that local antigen stimulation was not required for CD103 expression on Trm cells in the 
skin and salivary gland [118;119]. Interestingly, E-cadherin is contributed to retention of 
pathogen-specific Trm cells in the salivary glands, which E-cadherin may induce 
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homotypic adhesive interaction between Trm cells and epithelial cells [118]. These data 
suggest that maintenance of CD103 on Trm cells is dependent on local antigen or tissue 
microenvironment. 
 
In this chapter, my data showed that environmental-derived signals (TGFβ) tightly 
regulate the responses of virus-specific Teff and Tem cells in the lung. The TGFβ 
induces different responses from KLRG1- and KLRG1+ subsets of virus-specific Teff 
cells by selectively inducing apoptosis of short-lived Teff cells, but it induces survival of 
long-lived Teff cells via CD103 adhesion molecule in the lungs where are protected by 
the mucociliary escalator (Figure 3-9). Therefore these data provide a better 
understanding how TGFβ signaling pathway maintains virus-specific Teff and Tem cells 
in the lungs during influenza virus infection. In next chapter, I will discuss how TcR 
receptor-derived signals influence the phenotypes and numbers of activated virus-
specific Teff cells using two different strains such as persisting WSN-OVAI and non-
persisting X31-OVA viruses.  
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Figure 3-1. The numbers of KLRG1+ virus-specific effector CTLs were 
increased in the absence of TGFβ signals.  
(A) Experimental protocol and timeline. Mixed bone marrow cells (mixed 1:1 ratio) 
from B6 (WT) and dnTGFβRII (Mut) mice were transferred into B6 mice that were 
lethally irradiated. The recipient mice were infected with HKx31 virus ~8 weeks after 
reconstitution. MHCI tetramers were used to analyze influenza virus-specific CD8 T 
cells in different tissues 10 and 20dpi. The CD45.1/CD45.2 congenic markers were 
used to distinguish between host, WT and mutant cells. The tetramer positive cells in 
the lungs and spleen were divided into KLRG1+ (gray) and KLRG1- (white) subsets. 
(B) The numbers of NP-specific CTL and (C) the numbers of PA-specific CTL. Data 
from a pool of 3 animals is shown. Duplicate experiments gave similar results. 
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Figure 3-2. CD103 is selectively expressed on KLRG1- virus-specific 
CTLs.  
Mixed bone marrow cells (mixed 1:1 ratio) from B6 (WT) and dnTGFβRII (Mut) mice 
were transferred into B6 mice that were lethally irradiated. The recipient mice were 
infected with HKx31 virus ~8 weeks after reconstitution. MHCI tetramers were used 
to analyze influenza virus-specific CD8 T cells in different tissues 10 and 20dpi. The 
CD45.1/CD45.2 congenic markers were used to distinguish between host, WT and 
mutant cells. Separate subsets of KLRG1+ and KLRG1- NP-specific CD8 T cells 
were analyzed for CD69 and/CD103 expression. Data from 3 animals per group are 
shown. Duplicate experiments gave similar results. 
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Figure 3-3. The numbers of cytokine-producing CTLs in the lungs were 
increased when TGFβ signaling was blocked.  
(A) Experimental protocol and timeline. Bone marrow cells from B6 or dnTGFβRII 
mice were transferred into separate groups of B6 mice that were lethally irradiated. 
Bone marrow chimeric mice were infected with HKx31 virus ~8 weeks after 
reconstitution.  
(B) Lymphocytes were enriched 10dpi (3mice per group) for peptide stimulation in 
the presence of brefeldin A.  
(C) Lymphocytes were enriched 21dpi (3mice per group) for peptide stimulation in 
the presence of brefeldin A. The numbers of CD8 T cells expressing IFNγ alone 
(white), TNFα alone (black), or both cytokines (hatched) are shown. Statistical 
significance was determined using an unpaired students T test. Mean±SD from 3 
mice per group are shown. *P<0.05, **P<0.01. 
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Figure 3-4. Increased numbers of infiltrating leukocytes in the absence 
of TGFβ regulation in the lungs.  
Irradiated C57BL/6 mice were reconstituted with bone marrow cells from wild type or 
dnTGFBRII+ donor mice ~8 weeks before HKx31 infection. Inflated lungs were 
embedded in paraffin 10dpi and 4 micron sections were stained with hematoxylin and 
eosin. (A) Mixed donor cells no infection. (B & D) Wild type donor cells. (C & E) 
dnTGFβRII+ donor cells 10dpi. Photographs were taken at original magnification 10x 
and 60x. Duplicate experiments gave similar results. 
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Figure 3-5. TGFβ signaling is required for CD103 expression.  
(A) Experimental protocol and timeline. Equal numbers (106) of F5-WT and F5-
dnTGFβRII cells were transferred to B6 mice two days before E61-13-H17 infection.  
(B) The transferred F5 cells were analyzed using CD45.1 and CD45.2 congenic 
markers 9dpi. The bar graphs indicate the ratios of F5-WT (gray bar) and F5-
dnTGFβRII cells (open bar) in different tissues from 3 mice. Overlaid histograms 
show gated populations of transferred F5-dnTGFβRII (solid line) or F5-WT (gray 
shading) using representative animals from groups of 3. The percentages of cells that 
are positive for each marker are displayed for F5-WT (above the line) and F5-
dnTGFβRII (below the line) cells. Statistical significance was determined using an 
unpaired students T test. Mean±SD from 3 mice per group are shown (*P<0.05 
**P<0.01 and ***P<0.001). Duplicate experiments gave similar results. 
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Figure 3-6. Large numbers of KLRG1+ virus-specific CTL were 
distributed around the alveoli during the peak of the CTL response.  
(A) Experimental protocol and timeline. Mixed bone marrow cells (10:1 ratio) from B6 
or dnTGFβRII mice were transferred to irradiated B6 mice. Chimeric mice were 
received 103 naïve CD45.1+ (B & D) OTI-WT cells or (C & E) OTI-dnTGFBRII+ cells 
48 hours before infection with WSN-OVAI virus. The CD31 antibody was injected to 
stain endothelial cells 15mins before the lungs were harvested. Fragments of fixed 
lung tissue were stained with antibodies to Ep-CAM (red), CD31 (yellow) CD45.1 
(blue) and KLRG1 (green) 10 dpi. (b-e) Enlargements of the boxed regions. The 
Imaris imaging software was used to identify areas of overlapping blue and green 
staining (white regions) in the boxed regions.  
(F) Naïve CD45.1+ wild type OTI cells (blue) were analyzed for CD103 expression 
20dpi (green) with (f) overlapping blue and green staining on cells in the boxed 
region (white). Z-stack images were taken at original magnification 20x. Duplicate 
experiments gave similar results. 
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Figure 3-7. CD103 helps virus-specific CD8+ T cells stay in the lungs.  
(A) Experimental protocol and timeline. (B) Equal numbers (total 106) of OT-WT and 
OTI-CD103KO cells were transferred to B6 mice two days before WSN-OVAI 
infection. The transferred OTI cells were analyzed using CD45.1 and CD45.2 
congenic markers. The bar graphs indicate the frequencies of OTI-WT (black) and 
OTI-CD103KO cells (white) within the transferred cell population. Histograms from 
representative animals show gated populations of transferred OTI-CD103KO (white) 
or OTI-WT (black).  
(C) Equal numbers (total 106) of F5-WT and F5-CD103KO cells were transferred to 
B6 mice two days before E61-13-H17 infection. The mutant and wild type F5 cells 
were identified using CD45.1/CD45.2 congenic markers. The bar graphs indicate the 
ratios of F5-WT (black) and F5-CD103KO cells (white) in different tissues of 3 mice. 
Overlaid histograms from representative animals of each group show F5-CD103KO 
(white) or F5-WT (black). Statistical significance was determined using an unpaired 
students T test. Mean±SD from 3 mice per group are shown (*P<0.05 **P<0.01 and 
***P<0.001). Duplicate experiments gave similar results. 
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Figure 3-8. CD103 is required for retention of virus-specific CD8+ T cells 
in the lungs.  
(A) Experimental protocol and timeline. Equal numbers of CD45.1 OT-WT (103) and 
GFP+OTI-CD103KO (103) cells were transferred to GFP+2.3 mice two days before 
WSN-OVAI infection. The transferred OTI cells were analyzed using confocal 
microscopy using CD45.1 and GFP 10, 20 and 30dpi. Each color indicates OTI-WT 
(Blue), OTI-CD103KO (Green) and Ep-CAM (Red). The Ep-CAM antibody was used 
to mark the outer boundary of the airway.  
(B) Images show representative areas from each group 10, 20 and 30dpi.  
(C) The numbers of transferred cells were counted inside and outside the white line.  
(D) Colored dots (black, blue and red) indicate data from different animals. Statistical 
significance was determined using an unpaired students T test. Mean±SD from 
multiple images of 4 mice per group are shown (*P<0.05 **P<0.01 and ***P<0.001). 
Duplicate experiments gave similar results. 
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Figure 3-9. Model to show that TGFβ signaling induces different 
responses from KLRG1- and KLRG1+ virus-specific CTLs. 
(1) TGFβ plays a role in reducing the numbers of virus-specific CTLs which express 
KLRG1 in the lungs during acute viral infection  
(2) TGFβ-induced expression of CD103 is required for retention of newly activated 
virus-specific CTLs which do not express KLRG1 in the lungs during the recovery 
phase of the infection 
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CHAPTER IV: 
 
THE ROLE OF ANTIGEN IN CD8 T CELL MIGRATION TO THE LUNGS 
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ABSTRACT 
 
WSN-OVAI and X31-OVA are recombinant influenza viruses which express the 
SIINFEKL epitope. Both viruses induce strong immune responses in the lungs during the 
peak of the infection. When naïve CD8 T cells from OTI TcR transgenic mice were used 
to determine how long the SIINFEKL peptides were present in vivo they proliferated in 
the MLN more than 30dpi with WSN-OVAI virus, while no SIINFEKL peptides detected in 
the X31-OVA infected mice. Histological analysis revealed mild inflammatory responses 
in the lungs and MLN of both groups of animals 30dpi. We used MHCI tetramer analysis 
to compare the phenotypes of the endogenous virus-specific CD8 T cells in these 
animals. Larger percentages of OVA-specific CTL expressed CD69 and CD103 in the 
lungs when the SIINFEKL peptides were present. In addition, when the WSN-OVAI 
infected mice were treated with antibodies that recognize H-2Kb/peptide complexes, the 
percentages of OVA-specific CTL that expressed CD69 and CD103 decreased in the 
lungs. 
 
As CD69 is a marker of early antigen stimulation, I investigated whether CD69 
expression helps activated CD8 T cells reach the lungs during influenza virus infection. 
First we crossed F5 and OTI TcR transgenic mice with CD69KO mice to produce cells 
for transfer studies. When I transferred naïve CD8 T cells from the progeny animals to 
B6 mice before influenza virus infection, there were similar numbers of CD69KO and 
wild type CD8 T cells in most tissues 10dpi. In contrast, there were much larger numbers 
of wild type, than CD69KO, cells in the lungs. These data indicate that CD69 is required 
for efficient migration to the lungs. To visualize the transferred cells in situ we crossed 
the F5-WT and F5-CD69KO mice with other mice that express GFP in all cell types 
10dpi. When I used confocal microscopy to compare the distribution of wild type and 
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CD69KO cells in the lungs at 10 and 25dpi, there were no differences between F5-WT 
and F5-CD69KO. I also found that large numbers of CD69KO cells were in close 
association with the blood vessels in the lungs during the recovery phase of the infection. 
These data suggest that CD69 expression influences CTL migration in peripheral tissues 
such as the lungs.  
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INTRODUCTION  
 
Epithelial cells in the airways play an important role in viral replication. Cytotoxic T 
lymphocytes (CTLs) promote viral clearance from the lungs by inducing apoptosis 
through contact-dependent interactions [172]. Since direct interactions are required to 
induce apoptosis, the influenza virus-specific CTLs must migrate to the site of viral 
replication to kill the infected epithelial cells before they release new infectious virus 
particles.  
 
CD8 T cells undergo multiple steps of maturation after they respond to antigen 
stimulation [173]. During differentiation the activated CTLs change several surface 
markers which are required for activated T cells to move between different tissues in the 
body. Naïve and Tcm CD8 T cells respond to antigen simulation in the lymphoid tissues 
and must therefore express CCR7 and CD62L to enter into the lymph nodes via the high 
endothelial venules (HEV) [64]. Both subsets of cells also express CD127 (i.e. 
Interleukin-7 receptor alpha or IL-7Rα) which is important for survival and homeostatic 
proliferation [85]. The naïve CD8 T cells undergo multiple rounds of cell division after 
antigenic stimulation and differentiate into effector CD8 T cells (Teff) which have 
cytotoxic activity and produce cytokines [174]. During T cell activation CCR7, CD62L and 
CD127 are down regulated, while CD11a and CD44 are upregulated and promote 
extravasation to peripheral tissues, through interactions with intercellular adhesion 
molecule-1 (ICAM-1) and hyaluronic acid, respectively [175;176]. Most of the activated 
CTLs become short lived Teff cells, which die during the contraction phase of the 
response. The mechanisms that control the contraction are not completely defined, but 
data from our laboratory indicate that TGFβ-induced apoptosis plays an important role 
during influenza virus infection (Submitted for publication). 
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Members of our laboratory previously used parabiosis experiments to follow CTL 
migration in the blood stream and found that some non-migrating CD8 T cells stay in the 
lungs and MLN long after viral clearance, where they maintain stable CD69 and CD103 
expression [145]. Some of these virus-specific CD8 T cells also express PD-1 at low 
levels, which is a marker that is transiently expressed on all T cells soon after TcR 
signaling, but can also be a marker of functional exhaustion in situations of chronic 
inflammation [177;178]. 
 
Several studies have shown that some virus-specific CTLs maintain stable CD69 
expression in the lungs after respiratory infections [73;145;179], and as well as selection of 
other peripheral tissues including the skin, kidney, brain, salivary glands and guts 
[114;118;119]. This marker, which is also known as the early leukocyte activation antigen, is 
a type II membrane glycoprotein from the C-type lectin family [180]. The cytoplasmic tail 
of CD69 contains a calcium binding domain and cross linking leads to activation of 
ERK1/2 in CD4+ T cells [181]. The ligand for CD69 has not been clearly defined, but 
some studies suggest that CD69 interacts with complex oligosaccharides [182]. CD69 
expression can be transiently induced on CD8 T cells by activation of the TcR signaling 
pathway [183] or by exposure to type I interferon [184;185]. In an asthma model blockade of 
CD69 reduced the numbers of CD4 T cells in the lungs, which corresponded with 
reduced inflammation and suggests that CD69 is involved in CD4 T cell migration [186]. 
Some studies suggested that CD69 slows the rate of T cell exit from the peripheral 
lymph node by down regulation shpingosine-1-phosphate receptor 1 (S1PR1) following 
T cell activation [187;188]. The S1PR1 binds to CD69 and is required for T cells to enter the 
blood vessels in response to high concentrations shpingosine-1-phosphate (S1P) [189]. 
However, the role of CD69 in CTL migration into the peripheral tissues is largely 
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unknown. Other studies have shown that chemokine receptor CCR7 is also required for 
T cells leave peripheral tissues and enter the peripheral lymph nodes (pLNs) [190]. 
 
In this chapter, I will discuss how antigen persistence impacts the phenotypes of 
CD8 T cell in the lungs at different times during the response to influenza virus infection. 
Furthermore, I will discuss how antigen-induced CD69 expression regulates virus-
specific CTL migration and distribution in the lungs during the recovery phase of the 
infection. Members of our laboratory previously demonstrated that processed viral 
antigens persist in the respiratory tract (MLNs) for at least two months after WSN-OVAI 
infection, as demonstrated by weak proliferative responses by carboxyfluorescein 
succinimidyl ester (CFSE)-labeled naïve OTI cells in transfer studies [145]. Some 
endogenous virus-specific Teff cells also showed signs of a response to chronic antigen 
stimulation in the infected mice, including sustained PD-1 expression [191]. Other groups 
have also reported evidence of prolonged antigen presentation after infection with other 
strains of influenza virus [192;193]. In contrast, when naïve OTI cells were used to map 
antigen presentation after infection with the X31-OVA they could not detect SIINFEKL 
peptides beyond 15dpi [136]. I have used the persisting WSN-OVAI and non-persisting 
X31-OVA strains of influenza virus to determine how sustained presentation of 
pathogen-derived peptide antigens impacts the phenotype and migration patterns of 
influenza-specific Teff cells in the lungs and other tissues during memory development.  
 
The data that are presented in this chapter are divided between three specific aims. 
Each aim addressed a specific question about the way that antigen stimulation 
influences the numbers and phenotypes of virus-specific CD8 T cells in the lungs. 
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Aim 2.1. How does antigen persistence influence the resident T cell responses in 
the lungs?  
Aim 2.2. How does CD69 deficiency impact virus-specific CD8 T cell activation and 
distribution? 
Aim 2.3: How does the route of infection influence the local CTL response? 
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RESULTS 
Aim 2.1. How does antigen persistence influence the resident T cell responses in 
the lungs?  
 
Antigen persistence in the lungs after two distinct influenza virus infections. 
Previously members of our laboratory demonstrated that WSN-OVAI infection 
induced prolonged antigen presentation until 60dpi [145], but others showed that the X31-
OVA does not induced antigen persistence more than 15dpi [136]. I infected separate 
groups of B6 mice which were infected with either WSN-OVAI or X31-OVA virus to 
determine how long viral peptides persist in vivo. The mice were maintained for 20 and 
30days before I transferred 2x105 naïve CD45.1+ OTI cells to each mouse by i.v. 
injection. One week later I recovered lymphocytes from the MLN and analyzed the 
transferred cells for CFSE dilution, using the CD45.1 marker to gate on the proliferating 
OTI cells. Although very small numbers of transferred OTI cells divided in the MLN of the 
X31-OVA infected mice, there were many dividing OTI cells in the WSN-OVAI infected 
mice 26 - 36dpi (Figure 4-1). These data show that SIINFEKL peptides persist after 
WSN-OVAI infection, but not after infection with X31-OVA virus.  
 
MHCI tetramer analysis was used to phenotype endogenous virus-specific CD8 T cells 
in the lungs. 
Several groups have shown that large numbers of virus-specific CD8 T cells 
maintain stable CD69 expression in the lungs after infection with different strains of 
influenza virus including our studies with WSN-OVAI virus [146;179]. Since the experiments 
with transferred OTI cells showed that the WSN-OVAI and X31-OVA viruses differ in 
their ability to support prolonged antigen presentation [136;145], I used MHCI tetramer 
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analysis to compare the phenotypes of the endogenous virus-specific Teff cells in each 
group of animals. 
 
I infected separate groups of mice with either WSN-OVAI or X31-OVA and used 
tetramers that are specific for the NP and PA epitopes [140] to identify endogenous virus-
specific Teff cells in different tissues 10, 20 and 30dpi. Other antibodies were used to 
measure CD44, CD62, CD69, CD103, CD127 and PD-1 (Figure 4-2). The overlaid 
histograms show gated populations of virus-specific CD8 T cells from WSN-OVAI 
(dashed line) or X31-OVA (gray shading) infected mice. The percentages of tetramer-
specific CD8 T cells in the marked regions are displayed above the line for WSN-OVAI 
and below the line for X31-OVA virus. The tetramer-negative CD8 T cells were used to 
set the gates for phenotypic analysis. I used an unpaired student T-test to determine 
statistical significance among groups of 5 animals. 
 
This experiment showed that both viruses induced large numbers of OVA-, NP- 
and PA-specific CD8 T cells in the tissues by 10dpi, which shared very similar 
phenotypes (Figure 4-2A). By 20dpi some differences in the phenotypes of the cells from 
the two groups of animals became apparent. Specially, smaller numbers of tetramer 
specific CD8 T cells expressed CD69, CD103 and PD-1 in the lungs of the X31-OVA 
infected mice, than in the WSN-OVAI infected mice (Figure 4-2B). These differences 
were more significant by 30dpi (Figure 4-2C and 4-3A). These data suggest that 
prolonged antigen presentation induces more activated phenotype for virus-specific Teff 
cells in the lungs during the recovery phase of influenza virus infection. 
 
The tetramer studies showed larger numbers OVA-specific CD8 T cells in the 
lungs of the WSN-OVAI infected mice compared to the X31-OVA infected mice (Figure 
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4-3B). When I compared the ratios of cells in the lungs and lymphoid tissues from each 
animal 10dpi, I found that more than 70% of the total OVA-specific CTL population was 
located in the lungs of both groups of animals (Figure 4-3C). The percentages of OVA-
specific CTLs in the lungs of the WSN-OVAI infected mice remained the same until 30dpi. 
In contrast the percentage of the OVA-specific CTLs in the lungs of the X31-OVA 
infected animals declined to 35% by 30dpi (Figure 4-3C). These data show that a larger 
portion of the total OVA-specific CTL population stayed in the lungs when the SIINFEKL 
peptides were present. 
 
What is the evidence that antigen plays a role in prolonged T cell activation? 
To further confirm whether chronic antigen stimulation contributed to the 
activated phenotype of the pathogen-specific Teff cells in the lungs, I used a blocking 
antibody (25D1.16) which can bind to the peptide SIINFEKL (OVA peptide 257-264) 
when it is bound to a H-2Kb MHCI molecule. This antibody prevents interactions between 
the MHCI complex and the TcR [194]. The mice were infected with WSN-OVAI virus and 
treated twice with the 25D1.16 blocking antibodies (or an isotype control) at 20dpi 
(100μg i.n. plus 400μg i.v.) and 23dpi (250μg i.v.). MHCI tetramers and other antibodies 
were used to phenotype the virus-specific Teff cells in the lungs 29dpi. Overlaid 
histograms show gated populations of OVA-specific CD8 T cells in the lungs from 
isotype (dashed line) or 25D1.16 (gray shading) antibody treated mice (Figure 4-4A). 
The percentages of OVA-specific CD8 T cells that were positive for CD69 and CD103 
are displayed for isotype (above the line) and 25D1.16 (below the line) treated mice. 
This experiment showed that the total numbers of OVA-specific CD8 T cells in the lungs 
of mice that were treated with the blocking antibody were reduced, as compared to that 
in the lungs of isotype antibody-treated mice (Figure 4-4B). The blocking antibodies also 
decreased the percentages of CD69 and CD103+ OVA-specific CD8 T cells in the lungs. 
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Although CD103 was down-regulated on OTI cells in the BAL, CD69 expression was 
unchanged. In contrast, the phenotype and numbers of NP-specific CD8 T cells were 
similar in the 25D1.16 and isotype-treated groups. These data indicate that recent 
antigen stimulation reinforces the activated phenotypes of some virus-specific Teff cells 
in the lungs. 
 
Histology was used to examine the inflammatory response in the lungs. 
Since viral peptides were detected in the MLN long after infection with WSN-
OVAI virus, I used histological analysis to examine the inflammatory responses in the 
lungs during the recovery phase of infection. Again two groups of mice were infected 
either WSN-OVAI or X31-OVA virus and the lungs were harvested from groups of 3 mice 
10 and 30dpi. The inflated lungs were cut into sections and stained with H&E. These 
studies showed large numbers of leukocytes in the lungs 10dpi with both viruses. Many 
leukocytes were clustered in and around the airways and in the alveolar spaces (Figure 
4-5A and 4-5B). By 30dpi the leukocyte infiltration declined, but some mild inflammation 
was still detected in the lungs (Figure 4-5C and 4-5D). These data show that antigen 
persistence does not cause robust inflammatory responses in the lungs. 
 
Aim 2.2. How does CD69 deficiency impact virus-specific CD8 T cell activation and 
distribution? 
 
Does CD69 deficiency impact the kinetics of virus-specific CD8 T cell activation? 
A recent study demonstrated that CD69 can interact with sphingosine-1-
phosphate receptor 1 (S1PR1) which is required for lymphocyte egression from 
secondary lymphoid tissues and may thus influence the kinetics of the CTL response 
[187;188]. To determine whether CD69 expression influenced virus-specific CD8 Teff cell 
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activation, I used F5 mice that were crossed with CD69KO mice to generate F5-
CD69KO mice. To compare the rate of cell division in vivo, I labeled a mixed population 
of naïve CD8 T cells from F5-WT and F5-CD69KO cells with CFSE and transferred a 
total 106 F5 cells to each recipient, two days before infection with E61-13-H17 virus. The 
F5-WT and F5-CD69KO cells in the BAL, Lung, MLN and spleen were analyzed for 
CFSE-dilution on days 3, 5, 7 and 9 after infection, using the CD45.1/CD45.2 congenic 
markers. This experiment did not reveal any differences in the rate of cell proliferation by 
the two transferred populations at any time point analyzed (Figure 4-6A).  
 
Furthermore, I tested whether CD69-deficiency influenced virus-specific Teff 
function. A mixed population of F5-WT and F5-CD69KO cells (106) was transferred to 
the recipient mice two days before E61-13-H17 infection as before. Enriched CD8 T cells 
were recovered from the lungs and spleen 3 and 4dpi and stimulated for 5hr with 
synthetic F5 peptide (1μg/ml) and brefeldin A (BFA). Intracellular cytokine staining 
showed that CD69-deficient CTL can make IFNγ after in vitro stimulation (Figure 4-6B). 
 
Transfer studies were used to determine whether CD69 expression changes the CTL 
response in the lungs. 
Several studies have shown that virus-specific CTLs which maintain stable 
CD69 expression become greatly enriched in the lung airways after viral clearance 
[145;146]. To determine whether CD69 plays a role in CD8 T cell migration, I transferred a 
mixed population of F5-WT and F5-CD69KO cells (106) into the same recipients two 
days before E61-13-H17 infection. It was necessary to transfer both populations to the 
same recipients to ensure that they were exposed to the same inflammatory conditions 
and concentrations of antigen. At different times after infection (10, 20 and 30dpi) I used 
74
 
 
the CD45.1/CD45.2 congenic markers to compare the ratios of F5-WT and F5-CD69KO 
cells in different tissues (Figure 4-7A). 
 
Although I found almost equal ratios of F5-WT and F5-CD69KO cells in the 
spleen and MLN, there were consistently higher numbers of F5-WT cells in the lungs at 
all time points analyzed (Figure 4-7B). I also found that some F5-CD69KO cells 
accumulated in the spleen 20 and 30dpi. Other experiments did not reveal an 
accumulation of F5-CD69KO in the spleen. When I analyzed gated populations of F5 
cells for CD103 expression, I found that the absence of CD69 expression resulted in 
smaller percentages of CD103+ CD8 T cells than wild type cells in the lungs (Figure 4-
7B). These data indicate that the absence of CD69 causes inefficient CD8 T cell 
migration into the lungs. 
 
In addition, I investigated whether the absence of CD69 expression influenced 
the response of OVA-specific CTL in the lungs. Equal numbers of OTI-WT and OTI-
CD69KO cells (106 total) were transferred to recipient mice two days before WSN-OVAI 
infection and the CD45.1/CD45.2 congenic markers were used to track their response 
on different days after infection (i.e. 10, 20 and 30dpi). I found lower frequencies of OTI- 
CD69KO (~ 35%) in the lungs, as compared to the OTI-WT cells (~ 65%), at all time 
points analyzed (Figure 4-7C). Together, these data indicate that CD69 deficiency 
induce inefficient migration of virus-specific CD8 T cells to the lungs and consequently 
there is a selective reduction in the numbers of CD103+ cells in the lungs. 
 
Since CD69 and CD103 are expressed by the same cells, we generated 
CD69/CD103 doubleKO (DKO) cells by crossing F5-CD69KO with CD103KO mice. I 
transferred equal numbers (total 106) of F5-WT and F5-DKO cells into the same recipient 
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mice and analyzed the ratios of WT and mutant cells using the CD45.1 and CD45.2 
markers. I observed larger percentage of F5 WT cells compared to F5-DKO cells in the 
lungs 10dpi, which was similar to the CD69KO mice (Figure 4-7B). By 20dpi more F5 
WT cells were observed than F5-DKO cells in the BAL, but both cell ratios were similar 
in other tissues. There were equal ratios of transferred cells in the lungs and MLN 30dpi, 
but not in the spleen (Figure 4-8). My data showed that CD69 helps virus-specific CTL 
migration to the lungs during influenza virus infection. However, it is unknown why CD69 
deficiency did not influence virus-specific CTL migration in the absence of CD103. 
 
Does CD69 expression influence influenza virus-specific CTL location in the lungs? 
My data indicate that antigen-induced CD69 expression promotes efficient virus-
specific CTL migration into the lungs, as demonstrated by the in vivo competition studies. 
Next I also used scanning confocal microscopy to investigate whether CD69-deficiency 
changed the distribution of virus-specific CTLs in different anatomical compartments 
inside the lungs. To generate F5 cells that could be visualized after transfer, we crossed 
F5-CD69KO cells with Ubquitin-GFP mice which express GFP in all cell types [135] . 
Because GFP is recognized as a foreign antigen in B6 mice, I used GFP+ 2.3 mice as 
recipients, since they express GFP in the bone marrow and will tolerate the transferred 
GFP+ T cells [134]. Equal numbers of CD45.1+ F5-WT and GFP+ F5-CD69KO (2x104) 
cells were transferred into GFP+ 2.3 mice two days before E61-13-H17 infection. I used 
the CD45.1 marker and GFP to compare the distributions of transferred cells at different 
days after infection. To visualize the endothelial cells in the blood vessels, I gave CD31 
antibody via intravenous injection 15mins before lung harvest. Fragmented lung tissues 
were further stained with Ep-CAM antibody and the lung tissues were analyzed by 
confocal microscopy (Figure 4-10). 
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To compare the frequencies of transferred F5-WT and F5-CD69KO cells in the 
lung, I used the Imaris imaging software to make each blue and green cell in multiple 
images as shown in Figure 4-9. The light green beads mark GFP+ cells, while light blue 
beads mark the CD45.1 cells. The results of this study were consistent with the flow data 
and CD69-deficiency resulted in reduced numbers of F5 cells in the lungs at all time 
points analyzed (10 and 25dpi) and supported the idea that CD69 promotes influenza 
virus-specific CD8 T cells migrate into the lungs (Figure 4-10B and 4-10C). During the 
peak of CD8 T cell response larger numbers of F5-WT cells were embedded in the 
airways, as compared to the F5-CD69KO cells, but there was no difference in the 
numbers of F5-WT and F5-CD69KO cells in the lungs parenchyma (Figure 4-10B). By 
25 dpi larger numbers of F5-WT cells were detected in the airways and parenchyma 
compared to the F5-CD69KO cells, but the distribution between two cell types was not 
significantly different (Figure 4-10C). Furthermore, when equal numbers of CD45.1+ F5-
WT and GFP+ F5-DKO (2x104) cells were transferred into GFP+ 2.3 mice two days 
before E61-13-H17, infection more F5-WT cells were found in the lungs 10dpi and 25dpi, 
as compared to the F5-DKO cells (Figure 4-11A and 4-11B). Interestingly, by 25dpi 
many F5-DKO cells were positioned close to the blood vessels, as compared to the F5-
WT cells (Figure 4-11B).  
 
To analyze CD69 deficiency influenced their location between WT and CD69KO 
cells in the airways during the recovery phase of infection, the 104 CD45.1 F5-WT, or 
GFP+ F5-CD69KO, or GFP+ F5-DKO cells were transferred into each recipient two days 
before E61-13-H17 infection. CD45.1 and GFP were used to track distribution of 
transferred F5 cells. I injected CD31 antibody by i.v. 15 mins before lungs were 
harvested to stain endothelial cells. The lung tissues were further stained with Ep-CAM 
to stain lung epithelial cells 10 and 25dpi. The lung tissues were analyzed by confocal 
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microscopy (Figure 4-12). The imaging software was used to measure distances 
between the transferred cells and blood vessels. Colocalization was also used to detect 
cells that are touching or localized inside the blood vessels. To understand 3-dimentional 
space, isosurfacing was applied to give a constant volume of the blood vessels on the 
images, which provides more visualization of the small blood vessels. The frequencies of 
colocalized cells in the airways were calculated from multiple images of F5-WT, F5-
CD69KO and F5-DKO transferred groups by inserting beads as before. There was no 
different distribution between F5-WT, F5-CD69KO and F5-DKO cells in the airways10dpi 
(Figure 4-12A). My data showed that higher percentages of F5-CD69KO and F5-DKO 
cells were closely colocalized with the blood vessels 25dpi, compared to the F5-WT cells 
in the airways (Figure 4-12B and 4-12C). Table 1 indicates the cell numbers that are 
touching blood vessels in the airways using multiple images 25dpi. These suggest that 
CD69 helps influenza specific CTL migration efficiently and may play a role in 
egression/retention of virus-specific CTLs in the lungs during late stage of infection. 
 
Aim 2.3: How does the route of infection influence the local CTL response?  
 
CTL migration was analyzed after the different route of infection.  
A recent study suggested that the mucosal route of infection increased CD8 T 
cell migration into the lung airways after Sendai virus infection [195]. To further determine 
how the route of infection influenced the size and phenotype of the pathogen-specific 
CTL populations in the lungs, I infected B6 with recombinant Lister monocytogenes (LM-
OVA) by oral infection. For comparison another group of mice was infected intranasally 
with WSN-OVAI virus. At different times after infection I used MHCI tetramer analysis to 
compare the numbers of OVA-specific CD8 T cells in the tissues. 
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I found large numbers of OVA-specific CD8 T cells in the tissues from both 
groups of mice 10 and 20dpi, but smaller percentages of the OVA-specific CD8 T cells in 
the LM-OVA infected mice were found in the lungs, as compared to the WSN-OVAI 
infected mice (Figure 4-13A). Furthermore, the respiratory infection induced higher 
frequencies of OVA-specific CD8 T cells that expressed CD69 alone, CD103 alone and 
CD69 together with CD103 in the lungs, than the oral infection (Figure 4-13B). These 
data support the idea that a local route of infection caused larger percentages of the total 
pathogen-specific CD8 T cells to enter the lungs. 
 
I next used serial infections to investigate whether some circulating virus-specific 
memory CD8 T cells were recruited into the gastrointestinal tract during an oral LM-OVA 
infection and whether they became CD69 and/or CD103 in the absence of local antigen 
stimulation. The mice were first infected with HKx31 (i.n.) to generate virus-specific 
memory CD8 T cells. Six months later same mice were infected with LM-OVA by oral 
feeding. MHCI tetramer analysis showed that there were very few of NP- and PA-
specific CD8 T cells in the epithelium or lamina propria of the small intestine before oral 
infection, but some NP- and PA-specific CD8 T cells were located in the Peyer’s patches 
(Figure 4-14). 
 
After LM-OVA infection the numbers of NP-specific CD8 T cells in the epithelium of 
the small bowel increased, but the numbers of PA-specific CD8 T cells were unchanged. 
The numbers for both populations of influenza virus-specific memory CD8 T cells were 
increased in the lamina propria by 9dpi, while most virus-specific CD8 T cells had 
disappeared from the Peyer’s patches. As inflammation decreased the numbers of NP- 
and PA-specific CD8 T cells in the epithelium and lamina propria decreased and some 
virus-specific CD8 T cells reappeared in the Peyer’s patches by 15dpi (Figure 4-14B). 
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These data showed that some NP-specific CD8 T cells were recruited into the IEL and 
LP compartment during peak of inflammation. Most of the NP-specific CD8 T cells in the 
IEL compartments expressed both CD69 and CD103 at all three time points. In contrast 
the NP-specific CD8 T cells in the LP included approximately equal numbers of CD69-
single positive and CD69/CD103 double positive CTL, while the Peyer’s patches 
contained heterogeneous populations of NP and PA-specific CTL (Figure 4-14C). These 
data indicate that some NP-specific CD8 T cells can be recruited into the IEL and LP 
compartments by non-specific inflammation, where they express CD69 and CD103 
without local antigen stimulation, but the numbers quickly decrease as inflammation 
declines. 
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DISCUSSION 
 
Previously, members of our laboratory have shown that processed viral antigens 
persist in the MLN more than one month after infection with WSN-OVAI virus  [145]. In 
addition, this paper showed that CD11b+DCs present peptides to naive virus-specific 
CD8 T cells in the MLN during the late stage of the response [191]. These data are 
consistent with a recent finding that viral RNA is present in the lungs during the time that 
the viral peptides were present, as shown using nested PCR analysis [193]. Together 
these data suggest that new peptides may be produced from the persisting viral genome 
in the lungs. In contrast, others found that viral peptides do not persist more than 15 
days after infection with the X31-OVA virus [136]. I used these viruses to study how 
antigen persistence influences the phenotypes and numbers of virus-specific CTL in the 
lungs. My data showed that large percentages of endogenous influenza virus-specific 
CTL maintained an activated phenotype during late antigen presentation as shown by 
stable CD69 and CD103 expression in the lungs (Figure 4-2). CD69 as a marker for 
activation is transiently expressed by TcR stimulation [183]. Thus, these data suggest that 
persisting antigen presentation maintains activated Tem cells in the lungs, which have 
an important role in controlling secondary influenza virus infection. 
 
When I used 25D1.16 antibodies to block SIINFEKL with MHCI molecules, the 
blocking antigen presentation did not change the percentage of CD69+ OVA-specific 
CTLs in the airways, so it is possible that CD69 expression can be maintained by an 
antigen-independent mechanism at that site [72;196]. Although type I IFN can induce 
transient CD69 expression on CD8 T cells [184;185], another member of our laboratory did 
not find IFN mRNA by polymerase chain reaction (PCR) during the late stage of the 
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response (Tao Wu Unpublished data). These data support the idea that local antigen 
stimulation increases the numbers of CD69+ antigen-specific CTL in the lungs. 
 
Other studies demonstrated that CD69+ virus-specific Tem cells are greatly enriched 
in the airways and the lungs during recovery from respiratory infections including Sendai 
and influenza viruses [145;146]. The CD69 is a type II C-type lectin which is involved in 
lymphocyte migration [180]. However, it has not been investigated whether CD69 plays a 
role in influenza virus-specific CD8 T cell migration into the lungs or other peripheral 
tissues. A study has suggested that CD69 interacts with complex oligosaccharides which 
are expressed by epithelial cells [182]. In addition, there is evidence that CD69 has a role 
in CD4 T cell migration to the lungs [186], suggesting that CD69 expression may play a 
role in virus-specific CD8 T cell migration. My data are consistent with this idea, since I 
found that CD69 induces efficient virus-specific Teff cell migration into the lungs after 
influenza virus infection.  
 
My phenotypic data show that CD69 was expressed on tetramer-specific CTLs in the 
airways during the recovery phase from influenza virus infection as shown in Figure 4-2. 
Recent studies have demonstrated that CD69 directly interacts with S1PR1, which delay 
T cells egress from the secondary lymphoid organs [187].  This suggests that CD69 
deficiency may influence the kinetics of virus-specific Teff cell activation in the draining 
lymph node [187;188]. However, others also showed that the CD69-deficient CD8 T cells 
are able to proliferate at similar rate to WT CD8 T cells as demonstrated by BrdU ( 5-
bromo-2-deoxyuridine) incorporation [197]. In addition, my data showed that there was no 
significantly different between CD69KO and WT virus-specific Teff cells in the MLN. In 
addition, CD69KO virus-specific Teff cells are able to produce IFNγ after in vitro 
stimulation (Figure 4-6). Thus, CD69 deficiency does not influence influenza virus-
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specific CTL activation during early infection. It also has been implicated that S1PR1 
plays a role in T cell egress from the lymphoid organs and the skin tissue [187;198]. The 
finding that influenza virus-specific CD8 T cells maintained high levels of CD69 
expression in the lungs during late stage of infection suggests that the expression of 
S1PR1 on the cell surface is down regulated by direct CD69 interaction. My data 
demonstrated that more CD69KO virus-specific Teff cells are colocalized with the blood 
vessels in the airways, compared to the wild type virus-specific Teff cells. This suggests 
that more CD69KO virus-specific Teff cells are attracted toward S1P ligand gradient in 
the blood vessels (Figure 4-12). However, it is unknown how virus-specific Teff cells 
which express high levels of S1PR1 can reach the S1P ligand from the blood vessels. 
Since high concentration of S1P is maintained in the blood and lymphatic vessels [199], it 
is possible that influenza virus infection induces lung injury and S1P ligand leaks from 
the blood vessels. Since a S1P ligand plays a role in enhancing endothelial barrieral 
function in the lungs [200], high levels of S1P ligand may be produced by some 
endothelial cells when the endothelial cells are injured. Thus these data suggest that 
CD69 expression promotes Tem cells retain in the peripheral tissues. 
 
Recent work has shown that tissue-specific resident memory T cells (Trm) which are 
characterized by CD69 expression can persist in several different tissues such as the 
skin, gut, salivary gland, lung and brain in mouse models and human [80;114-118]. For 
example, a recent study showed that resident memory CTLs which express CD69 and 
VLA-1 are detected in the epithelial layer of the skin after herpes simplex virus (HSV) 
clearance [119]. Previously, members of our laboratory showed that CD69+ virus-specific 
Tem cells are maintained in the lungs several months after influenza virus infection [145]. 
These suggest that the activated virus-specific Teff cells are mostly located in the 
tissues that have recovered from a recent viral infection. However, others showed that 
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local antigen stimulation is not required for CD69 expression on Trm cells. A recent 
study has shown the naïve CD8 T cells can enter IEL compartment of the GI tract during 
homeostatic proliferation and become CD69+ CD8 T cells which does not express PD-1 
which is a marker for recent antigenic stimulation [114]. These data suggest that the 
generation and maintenance of Trm cells vary in different tissues. 
 
In contrast to Trm, virus-specific Tem cells can be recruited from the circulation into 
the lungs following heterologous virus infection [73]. My data showed that NP-specific 
memory CD8 T cells are recruited into both the IEL and LP 9dpi with LM-OVA infection, 
but PA-specific CTLs increase in numbers only in the LP (Figure 4-14). These recruited 
virus-specific Tem cells in the GI tract express high percentages of CD69 and CD103 
without antigen stimulation. It is consistent with data that CD8+ intraepithelial 
lymphocytes express CD69 in the absence of cognate antigen stimulation in the gut [201], 
implying that microenvironment provides specific signal to induce CD69 expression 
[114].When inflammation declined the numbers of NP-and PA-specific Tem cells are 
decreased in the small intestines, suggesting that local antigen presentation enhances 
virus-specific Tem retention in the peripheral tissues. 
 
In this chapter, my data showed that antigen persistence in the lungs increases the 
numbers of antigen-specific Tem cells which express CD69 and CD103. In vivo 
competition studies demonstrated that CD69 deficiency induces inefficient influenza 
specific-CTL migration to the lungs. Confocal microscopy analysis demonstrated that 
CD69 deficiency induces different distribution of virus-specific Tem cells which are 
closely located or colocalized in the blood vessels. Thus, the role of CD69 expression 
promotes efficient migration of antigen-specific Teff cells into the lungs and may 
enhance virus-specific Tem cells stay in the airways long after infection by down-
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regulating S1P1 receptors. Interestingly, bystander influenza virus-specific Tem cells 
which express CD69 without cognate antigen stimulation can be recruited into the GI 
tracks during small intestine inflammation.  
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Figure 4-1. Different influenza virus strains vary in their ability to 
support antigen persistence in the mediastinal lymph node (MLN). 
CFSE-labeled naïve OTI-WT cells were transferred to each group of mice 20 and 30 
days after infection with either WSN-OVAI or X31-OVA. The OTI cells were analyzed 
using CD45.1 congenic. The MLNs of 3 mice per group were analyzed for CFSE 
dilution 7 days after transfer. Histograms from representative animals show gated 
populations of transferred OTI cells. Duplicate experiments gave similar results. 
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90
Figure 4-2. The presence of antigen changes the phenotypes of virus-
specific CTL in the lung. 
(A-C) C57BL/6 mice were infected with either WSN-OVAI or X31-OVA virus. MHCI 
tetramers were used to analyze influenza virus-specific CD8 T cells in different 
tissues 10, 20 and 30dpi. Histograms indicate representative animals from each 
group of 5 mice. Overlaid Histograms show gated populations of tetramer-specific 
CD8 T cells from WSN-OVAI (dashed line) or X31-OVA infected mice (gray shading). 
The percentages of cells that are positive for each marker are displayed for WSN-
OVAI (above the line) or X31-OVA infected mice (below the line). Statistical 
significance was determined using an unpaired students T test. Mean±SD from 3-5 
mice per group are shown. (*P<0.05, **P<0.01 and ***P<0.001). Duplicate 
experiments gave similar results. 
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Figure 4-3. The antigen persistence increases the numbers of activated virus-
specific CTL in the lung. 
(A) The OVA-specific CD8 T cells from the WSN-OVAI or X31-OVA infected mice were 
analyzed for CD69 and/CD103 expression. MHCI tetramers were used to analyze influenza 
virus-specific CD8 T cells in the lungs 30dpi. 
(B) The numbers of OVA-specific CD8 T cells were counted in different tissues 10 and 30 dpi 
with WSN-OVAI (white) or X31-OVA (black) virus. Bar graphs indicate the number of OVA-
specific CD8 T cells in different tissues.  
(C) Comparison of OVA-specific CD8 T cells in the lungs and secondary lymphoid organs. 
The percentages were calculated from the total OVA-specific CD8 T cells in the tissues after 
infection with WSN-OVAI (white bar) or X31-OVA (black bar) infected mice. Statistical 
significance was determined using an unpaired students T test. Mean±SD from 3-5 mice per 
group are shown. (*P<0.05, **P<0.01 and ***P<0.001). Duplicate experiments gave similar 
results. 
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Figure 4-4. Interactions with MHCI molecules keep OVA-specific CTL 
activated during the late stage of the infection. 
(A) The WSN-OVAI-infected mice were injected with blocking 25D1.16 or isotype 
antibodies 20 and 23 dpi. The numbers and phenotypes of virus-specific CD8 T cells 
were analyzed 6 days later in the lungs. Histograms indicate representative animals 
from each group of 3 mice. Overlaid Histograms show gated populations of tetramer-
specific CD8 T cells after treatment with isotype (dashed line) or 25D1.16 antibodies 
(gray shading). The percentages of cells in the marked region are displayed for 
isotype (above the line) and 25D1.16 (below the line).  
(B) Bar graphs indicate the numbers of virus-specific CD8 T cells in the lungs from 
isotype (white bar) or 25D1.16 (gray bar) antibody treated mice. Statistical 
significance was determined using an unpaired students T test. Mean±SD from 3-5 
mice per group are shown. (*P<0.05, **P<0.01 and ***P<0.001). Duplicate 
experiments gave similar results. 
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Figure 4-5. There is mild inflammation in the lungs during late antigen 
presentation.  
Mice were infected with (A & C) WSN-OVAI or (B & D) X31-OVA virus. Inflated lungs 
were embedded in paraffin 10dpi and 4 micron sections were stained with H&E (A & 
B) 10dpi and (C & D) 30dpi.  
(E) The lung tissues from uninfected B6 mice were used as a control group. 
Photographs were taken at 10x magnification (aw = airway). Similar results were 
obtained from two independent experiments. Duplicate experiments gave similar 
results. 
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Figure 4-6. CD69-deficiency does not have a major impact on CTL 
activation or IFNγ production.  
(A) Equal numbers of CFSE-labeled naïve F5-WT and F5-CD69KO cells (total 106) 
were transferred to the same recipient mice two days before infection with E61-13-
H17. The dividing F5 cells were analyzed using CD45.1 and CD45.2 markers in 
different tissues 3, 5, 7 and 9dpi. The dot plots show a representative animal from 3 
mice.  
(B) Equal numbers of CFSE-labeled F5-WT and F5-CD69KO cells (1x106) were 
adoptively transferred to the same recipient mice two days before E61-31-H17 
infection. The dividing F5 cells were analyzed using CD45.1 and CD45.2 markers in 
the different tissues 3 and 4dpi. Lymphocytes were enriched in the lungs, MLN and 
spleen after peptide stimulation in the presence of brefeldin A. The percentages of 
IFNγ producing CD8 T cells are shown. Duplicate experiments gave similar results. 
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Figure 4-7. CD69 expression is required for efficient CTL migration to the 
lungs.  
(A) Experimental protocol and timeline.  
(B) Equal numbers of F5-WT and F5-CD69KO cells (total 106) were transferred to B6 
mice two days before E61-13-H17 infection. The transferred F5 cells were analyzed 
using CD45.1 and CD45.2 congenic markers in different tissues 10, 20 and 30dpi. 
The bar graphs indicate the frequencies of F5-WT (black) and F5-CD69KO (white) 
cells within the transferred cell population. Histograms from representative animals 
show gated populations of transferred F5-CD69KO (white) or F5-WT (black). 
Statistical significance was determined using an unpaired students T test. Mean±SD 
from 3 mice per group are shown (*P<0.05 **P<0.01 and ***P<0.001). Similar results 
were obtained from three independent experiments.  
(C) Equal numbers (total 106) of OT-WT and OTI-CD69KO cells were transferred to 
B6 mice two days before WSN-OVAI infection. The mutant and wild type OTI cells 
were identified using CD45.1/CD45.2 congenic markers in different tissues 10, 20 
and 30dpi. The bar graphs indicate the ratios of OTI-WT (gray) and OTI-CD69KO 
cells (white) within the transferred cell population. Histograms from representative 
animals show gated populations of transferred OTI-CD69KO (white) or OTI-WT 
(gray). Duplicate experiments gave similar results. 
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Figure 4-8. Dual CD69/CD103KO induces inefficient migration of virus-
specific CD8 T cells into the lungs.  
Equal numbers (total 106) of F5-WT and F5-DKO cells were transferred to B6 mice 
two days before E61-13-H17 infection. The transferred F5 cells were analyzed using 
CD45.1 and CD45.2 congenic markers. The bar graphs indicate the frequencies of 
F5-WT (gray) and F5-DKO (white) cells within the transferred cell population. 
Overlaid histograms indicate representative animals from each group of 3 mice. The 
percentages of cells that are positive for each marker are displayed for F5-WT 
(above the line) or F5-DKO (below the line) cells. Statistical significance was 
determined using an unpaired students T test. Mean±SD from 3 mice per group are 
shown (*P<0.05 **P<0.01 and ***P<0.001).  
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106
 Figure 4-9. The imaris software is used to count the transferred CD8 T 
cells. 
 (A) Equal numbers of CD45.1 F5-WT (104) and GFP+ F5-CD69KO (104) cells were 
transferred to 2.3 mice two days before E61-13-H17 infection. The transferred OTI 
cells were analyzed using confocal microscopy using CD45.1 and GFP 17dpi. Each 
color indicates F5-WT (Blue), F5-CD69KO (Green), CD31 (Yellow) and Ep-CAM 
(Red). The Ep-CAM antibody was used to mark the outer boundary of the airway. (B) 
The numbers of transferred F5 cells were counted using Imaris imaging program.   
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Figure 4-10. Dual transfers were used to show that CD69 deficiency 
reduces the numbers of virus-specific CD8 T cells in the lungs.  
(A) Experimental protocol and timeline. Equal numbers of CD45.1 F5-WT (104) and 
GFP+F5-CD69KO (104) cells were transferred to GFP+2.3 mice two days before 
E61-13-H17 infection. The transferred F5 cells were analyzed using confocal 
microscopy using CD45.1 and GFP (B) 10 and (C) 25dpi. Each color indicates F5-
WT (Blue), F5-CD69KO (Green), CD31 (yellow) and Ep-CAM (Red). The Ep-CAM 
antibody was used to mark the outer boundary of the airway. The numbers of 
transferred cells were counted inside and outside the white line. 4 animals gave 
similar results. 
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Figure 4-11. Confocal microscopy was used to analyze the distribution 
of dual CD69/CD103KO cell in the lungs.  
Equal numbers of CD45.1 F5-WT (104) and GFP+F5-DKO (104) cells were 
transferred to GFP+2.3 mice two days before E61-13-H17 infection. The transferred 
F5 cells were analyzed using confocal microscopy using CD45.1 and GFP 10 and 
25dpi. Each color indicates F5-WT (Blue), F5-DKO (Green), CD31 (yellow) and Ep-
CAM (Red). The Ep-CAM antibody was used to mark the outer boundary of the 
airway. Images show representative areas from each group (A) 10dpi and (B) 25dpi. 
a & c show around the airways, but b & d display the parenchyma. The numbers of 
transferred cells were counted inside and outside the white line. Multiple animals 
gave similar results.  
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Figure 4-12. Confocal microscopy shows that many CD69KO cells are 
close to the blood vessels during late antigen presentation. 
2.3 mice were received either CD45.1 F5-WT (104), or GFP+F5-CD69KO (104), or 
GFP+F5-DKO cells two days before E61-13-H17 infection. The transferred F5 cells 
were analyzed in the lungs using confocal microscopy (A) 10dpi and (B) 25dpi. GFP 
(green), CD31 (blue) and Ep-CAM (Red). The Ep-CAM staining was used to mark 
the outer boundary of the airways. (B) Colocalization analysis and isosurfacing were 
performed using the Imaris imaging software 25dpi. Magenta indicates contacts 
between the F5 cells (green) and the blood vessels (blue). a-c show the airways for 
F5-WT, F5-CD69KO and F5-DKO cells, respectively.  
(C) Cumulative data from multiple fields. Red and black indicate data from different 
animals analyzed 25dpi with E61-13-H17. The cell numbers are shown in table 4-1. 
Statistical significance was determined using an unpaired students T test. Mean±SD 
from multiple images of 4 mice per group are shown (*P<0.05 **P<0.01 and 
***P<0.001). Duplicate experiments gave similar results. 
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Table 4-1:
Numbers of contacts with vessels
Mouse # WT % Contact
1
2/48
32/107
12/63 15.7±5.6
5/51
2
6/71
5/74
4/65 7.3±0.3
6/87
5/62
Numbers of contacts with vessels
Mouse # CD69KO % Contact
1
26/54
9/45
6/38 29.3±5.9
23/62
15/59
2
33/55
36/73
30/126 36.2±7.9
13/71
13/44
Numbers of contacts with vessels
Mouse # DKO % Contact
1
20/90
16/93
42/133 23.7±4.2
2
33/115
42/120
31.9±3.2
C
A
B
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Table 4-1. The numbers of virus-specific effector CTLs colocalized with 
the blood vessels.  
Either (A) CD45.1+ F5-WT (104), or (B) GFP+ F5-CD69KO, or (C) GFP+ F5-DKO 
cells were transferred to the separate GFP+2.3 recipient mice one day before E61-
13-H17 infection. The transferred F5 cells were analyzed using GFP+ and CD45.1 
congenic marker 25dpi. The numbers of cells that were touching blood vessels are 
shown as a fraction of the total cells in the field. 
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 Figure 4-13. The route of infection changes the distribution of virus-
specific CD8 T cells in mucosal tissues.  
C57BL/6 mice were infected with either WSN-OVAI (i.n.) or LM-OVA (oral feeding). 
MHCI tetramers were used to analyze influenza virus-specific CD8 T cells in different 
tissues 10 and 20dpi.  
(A) The numbers of OVA-specific CD8 T cells in the BAL, Lungs and spleens were 
compared between WSN-OVAI and LM-OVA infected mice.  
(B) The OVA-specific CD8 T cells from the WSN-OVAI or LM-OVA infected mice were 
analyzed for CD69 and/CD103 expression. Statistical significance was determined 
using an unpaired students T test. Mean±SD from multiple images of 4 mice per 
group are shown (*P<0.05 **P<0.01 and ***P<0.001). Duplicate experiments gave 
similar results. 
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Figure 4-14. Bystander virus-specific memory CTLs are recruited in the 
small intestine during local infection with LM-OVA.  
(A) Experimental protocol and timeline. C57BL/6 mice were infected with the 
HKx31virus. B6 mice were infected with LM-OVA (oral) 6 months after influenza virus 
infection (i.n.). MHCI tetramers were used to analyze influenza virus-specific CD8 T 
cells. (B) The numbers of NP- and PA-specific memory CTLs were counted in 
different regions of the small bowel 9 and 15dpi. (C) CD69 and/CD103 expression on 
NP- and PA-specific memory CD8 T cells after LM-OVA infection. Duplicate 
experiments gave similar results.  
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DISSCUSSION AND CONCLUDING REMARKS 
 
The objective of this thesis was to investigate how virus-specific Trm cells protect 
the lungs during the recovery from a local viral infection. Previously, members of our 
laboratory used parabiosis studies to show that virus-specific CTLs which express CD69 
and CD103 in the lung airways are non-migratory cells (Figure 5-1) [145]. Studies of 
humans also show that a large numbers of Trm cells can be found in the non-inflammed 
lungs, which express CD69, CD103 and VLA-1 [115]. These lung Trm cells have the 
ability to produce cytokines including TNFα, IFNγ, IL-4, and IL-17 after in vitro 
stimulation using heat killed influenza virus-pulsed APCs [115]. A previous study has 
shown that VLA-1+ influenza virus-specific CD8 T cells in the lungs provide immediate 
protective immunity against secondary challenge [80], however the role of CD103 on Trm 
cells is largely unknown. 
 
Trm cells provide immediate heterosubtypic immunity.  
Virus-specific memory CD8 T cells are heterogeneous populations that can be 
divided into distinct subsets including Tcm and Tem. The Tem cells preferentially 
circulate nonlymphoid tissues, while Tcm cells circulate between the blood and 
secondary lymphoid tissues [113]. The numbers of circulating Tem cells decline over time, 
since they progressively lose the ability to migrate into the peripheral tissues [202]. 
Resident populations of Trm cells have been found in many different tissues including 
the skin, gut, salivary gland, lung and brain [80;114-116;118;119]. Some studies found that 
local antigen stimulation was required for induction and maintenance of CD103 
expression on Trm cells in the brain and lungs [115;116;171]. In contrast, others suggest that 
local antigen stimulation is not necessary for chronic CD103 expression on Trm cells in 
the skin and salivary gland [118;119]. The best evidence that Trm can promote immunity 
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comes from skin models which were used to show that Trm cells contribute to protection 
against reinfection with HSV by accelerating viral clearance [119]. 
 
Many studies have shown that activated virus-specific CD8 T cells which express 
CD69 and CD103 also become greatly enriched in the airways after respiratory virus 
infections [73;145;146;179]. These virus-specific Trm cells persist in the lungs for several 
months and are believed to mediate an accelerated response to reinfection by making 
IFNγ and other proinflammatory cytokines that recruit other immune cells into the local 
tissues. Although these cells are not lytic, they can acquire cytolytic activity after 
proliferation in response to antigen [146;203]. Most resting Trm cells in the airways do not 
constitutively express perforin and granzyme B, but after in vitro peptide stimulation they 
are capable of making cytotoxic molecules [204].  
 
CD103 enhances virus-specific CTL function. 
The reason that airway resident Trm cells lack cytotoxic activity may be related to 
the loss of CD11a expression [72;73], which can be cleaved by metalloproteinase-9 
(MMP-9) expressed by macrophages [74]. LFA-1 is the adhesion molecule that promotes 
cytolytic activity by stabilizing the interactions between CTLs and target cells, resulting 
in granule polarization [72;205]. Since CD103 is an adhesion molecules which promotes 
interactions with epithelial cells [206], it is possible that CD103 provides an alternative 
mechanism for virus-specific CTL to kill infected cells in the airways. Evidence to 
support this idea comes from transplanted  islet allografts which are not rejected in host 
mice that lack CD103 expression, but transfer of CD103+ CD8 T cells into the mice 
promotes rejection of the allografts [207]. In addition, another study demonstrates that the 
engagements of CD103 and E-cadherin played a role in the destruction of lung tumor 
cells by CTLs through granzyme B polarization and exocytosis in vitro, when 
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CD11a/ICAM-1 interactions were blocked [208]. These studies suggest that CD103 
expression on CTL can promote lytic activity toward epithelial cells that express E-
cadherin. 
 
Lung epithelial cells that express E-cadherin are major targets for influenza virus 
replication. Since CD103 is an adhesion molecule that plays a role in CTL migration to 
mucosal tissues [206], I investigated whether virus-specific CTL migration after influenza 
virus infection. Interactions with E-cadherin are believed to enhance the adhesion 
properties of virus-specific CTLs during interactions with epithelial cells [209]. My in vivo 
competition studies (Figure 3-7) demonstrate that CD103 deficiency does not impact 
virus-specific CTL migration during acute viral infection, but reduces the ability of virus-
specific CTLs to stay in the lungs during the recovery stage of the infection. Other 
studies also show that CD103 expression on virus-specific CTLs has a role in motility. A 
recent study shows that E-cadherin in vitro culture influences the movements of CD103+ 
cells by increasing cellular protrusions and filopodia [210], suggesting that their 
interactions play roles in cell motility and morphology.  I found smaller numbers of CTL in 
the lungs when CD103 not expressed. The biggest difference was late stage of the 
infection which was consistent with a role in retention not migration. 
 
TGFβ regulates the numbers of Teff cells during viral infection. 
My data show that TGFβ is required for CD103 expression on virus-specific CTLs 
(Figure 3-5). TGFβ is a pleiotrophic cytokine which controls a variety of cellular 
processes including cell death [106]. A recent study showed that TGFβ selectively 
induces apoptosis of  KLRG1+virus-specific Teff cells in LCMV infected mice during 
early clonal expansion using dnTGFβRII mice [107]. I used the same animals to examine 
how TGFβ signals influences CTL responses in the lungs and found much larger 
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numbers of virus-specific CTLs which expressed KLRG1 in the lungs and spleen when 
TGFβ signals were blocked (Figure 3-1). In addition, these KLRG1+cells were capable 
of making proinflammatory cytokines, including IFNγ and TNFα following in vitro 
stimulation with synthetic peptides. 
 
Since IFNγ and TNFα can cause severe immunopathology [152;153], I used 
histological analysis to examine whether blockade of TGFβ signals induced severe lung 
pathology in the influenza virus infected lungs. My data showed that there were 
extensive areas of inflamed tissue in the lungs including large numbers of infiltrating 
leukocytes in the dnTGFβRII+ mice during the peak of CTL response. However, the wild 
type animals showed more extracellular exudates and evidence of hemorrhage than the 
dnTGFβRII+ mice (Figure 3-4). Surprisingly, there were no dead animals in either group 
of mice. There are a couple of possibilities which may explain why the infection did not 
kill any animals in the absence of TGFβ signals. First, the animals were infected with 
HKx31 which is a mildly pathogenic strain. Second, larger numbers of virus-specific CTL 
may have accelerated viral clearance in the lungs of the dnTGFβRII+ mice. To confirm 
whether influenza viruses are cleared faster in the dnTGFβRII+ animals, we will 
measure the kinetics of viral clearance after infection with HKx31virus using a plaque 
assay. In addition we will analyze the pathology at earlier time points after infection with 
HKx31 and WSN-OVAI which is a more pathogenic strain. 
 
KLRG1 is another cell surface molecule can interact with E-cadherin on epithelial 
cells. Since the engagements of KLRG1 with E-cadherin inhibit downstream NFAT 
pathway , which reduces IL-2, TNFα and Fas ligand (CD94L) [168], this pathway could be 
third mechanism that stops the dnTGFβRII+ animals from dying. Although the blockade 
of TGFβ signals increased the numbers of KLRG1+ virus-specific CTLs in the lungs, 
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these cells did not express CD103 which means that KLRG1 and CD103 did not 
compete with each other to interact with E-cadherin. Repeated interactions between 
KLRG1 and E-cadherin may reduce the effector function of virus-specific CTLs.  
 
Our data show that the CTLs which expressed CD103 in the lungs of the WT 
mice were located in the airways during the recovery phase of the infection. These data 
indicated that TGFβ signals selectively regulate the survival of different subsets of virus-
specific CTLs during influenza virus infection, and also change distribution of Trm cells 
which express CD103. TGFβ can use multiple signaling pathways to alter cell 
differentiation and apoptosis. At this time we do not know whether one or two TGFβ 
signaling pathways regulate the CTL response. 
 
Antigen-induced signals increase the numbers of Trm cells in the lungs. 
CD69 is transiently induced on CD8 T cells by activation of the TcR signaling 
pathway [183] or by exposure to type I interferon [184;185]. Since large percentages of 
endogenous virus-specific CTLs express CD69 in the lung airways during the recovery 
from the influenza virus infection [145], I investigated how antigen persistence changed 
the numbers and phenotypes of virus-specific CTL in the lungs during the late stage of 
the infection using recombinant influenza viruses. WSN-OVAI and X31-OVA both 
express the SIINFEKL epitope [136], but differ in the ability to support antigen persistence 
(Figure 4-1). When I followed the phenotypic markers on the endogenous CD8 T cells, 
antigen persistence increased the numbers of recent activated antigen-specific CTLs 
which express CD69 in the airways and the lungs (Figure 4-2).  In addition blocking 
SIINFEKL:MHCI complex by injecting  25D1.16 antibody showed reduced numbers of 
OVA-specific CTLs which express CD69 and CD103 in the lungs (Figure 4-4A and 4-4B). 
In contrast, there were decreased numbers of OVA-specific CTLs in the airways, but the 
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percentages of CD69+ cells were unchanged. Micro array data prepared by another 
member of our laboratory did not reveal prolonged expression of type I IFN mRNA in the 
lungs 30dpi. However, we did not examine expression levels of type III IFN which may 
induce CD69 expression. My data show that antigen presentation is required for CD69 
expression on virus-specific CTLs in the lungs parenchyma, but may not be essential in 
the airways, during the late stages of the infection.  
 
CD69 signals regulate immune responses of virus-specific CTLs in the lungs. 
Large amounts of TGFβ can be produced by a variety of cells in the lungs 
including epithelial cells, fibroblasts, stromal cells, macrophages, T cells, and some DCs 
[106;160;161]. The TGFβ is secreted as an inactive form called LAP which can be activated 
by several different enzymes including TSP-1 protease, integrin αvβ6 and some 
influenza virus NA [163;164].  Interestingly, it has been suggested that CD69 has a 
regulatory role by inducing expression of the LAP TGFβ form. Previous studies show 
evidence that cross-linking CD69 using monoclonal antibody induces activation of ERK 
signaling pathway which is further involved in TGFβ expression in CD4 T cells [211;212], 
but whether CD69 can induce TGFβ expression in CD8 T cells is not known. 
  
CD69-deficient mice also develop autoimmune diseases, including arthritis and 
autoimmune myocarditis as well as contact dermatitis and allergic asthma, which 
suggest that CD69 has an inhibitory role in the pathogenesis of some diseases. A recent 
study supports the idea that CD69 engagements activate Jak3/Stat5 pathway which 
induces IL-2 and TGFβ production, resulting in inhibition of Th17 differentiation [213;214]. 
Similarly, CD69 deficiency in mice can influence inflammatory responses by enhancing 
Th0 into Th17 differentiation [214]. Therefore, CD69 signals regulate the immune balance 
through TGFβ that plays a role in differentiation naïve T cells into either regulatory T 
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cells or Th17 cells [215].   
 
CD69 plays a role in T cell migration. 
S1P is a ligand for S1PR1 and high concentration of S1P is maintained in the 
blood and lymphatic vessels. Several studies suggest that CD69 plays a role in T cell 
migration. The S1PR1 is required for T cell egress the secondary lymphoid organs [189]. 
CD69 slows the rate of T cell exit from the peripheral lymph node by down regulation 
S1PR1 following T cell activation [187;188]. The transmembrane and membrane proximal 
domains of CD69 directly bind to helix 4 of S1PR1, which induces a conformational 
change that may provide a higher affinity for S1P to down regulates CD69-S1P1 
complex [216]. My confocal microscopy studies support the idea that some CD69-
deficient Trm cells are closely colocalized with the blood vessels during the recovery 
from the influenza virus infection (Figure 4-12B). These data imply that CD69KO cells 
maintain high levels of S1PR1 on the surface and are therefore attracted to the blood 
vessels by an S1P gradient (Figure 5-2). Our studies suggest that inflammation-induced 
CD69 expression on virus-specific CTLs override S1P gradient. When CD69 is not 
expressed, inflammation may be also sufficient. However, inflammation and CD69 are 
absent, the S1P gradient becomes dominant. To investigate this possibility, I will use 
FTY720 which can bind to S1P receptors to block cell surface expression. 
 
In this thesis I investigated whether CD69 and CD103 are necessary for Trm cell 
to populate the lungs. My data show that TGFβ kills KLRG1+ CTLs, while Trm cells 
express CD103. In vivo competition studies show that CD69 alters CTL migration, while 
CD103 is required for retention of Trm cells in the lungs. These data indicate that TGFβ 
protects the lungs from immune damage and also plays a role in protective immunity 
during the infection with a new strain of influenza virus. 
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Figure 5-1. Parabiosis has been used to follow CD8 T cell migration in 
the blood and the spleen. 
Parabiosis is a surgical technique that can be used to join the blood supply of two 
animals. In the diagram, one mouse was infected with HKx31virus, while the other 
mouse was not infected. One month later the infected mouse was surgically 
conjoined with naïve mouse and CD45.1/2 congenic markers were used to follow 
CD8 T cell migration 15days after surgery. The data showed that some (1) Tem and 
(2) Tcm cells migrate to the lungs of the partner animal, but they do not express 
CD69 and CD103. In constrast some (3) Trm cells stay in the lungs of immune 
mouse long after viral clearance, where they maintain stable CD69 and CD103 
expression 
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Figure 5-2. CD69 may regulate virus-specific CTL migration to the 
peripheral tissues. 
Blood vessels contain high concentrations of shpingosine-1-phosphate (S1P). (1) 
Naïve CD8 T cells circulate between the blood and secondary lymphoid organs using 
the S1PR1. (2) Activated CTLs enter the peripheral tissues in response to 
inflammation. When inflammation subsides, Tem cells lose CD69 expression and 
return to the lymphatic vessels in response to S1P. (3) Data suggest that this 
pathway does not apply to mucosal tissues, where Trm cells do not lose CD69 
expression. When CD69 is not expressed, some Trm cells may artificially collect 
around the blood vessels which also contain high concentration of S1P. 
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